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Abbreviations 
 
Ab: antibody 
BBB: blood brain barrier 
BDNF: brain derived neurotrophic factor  
bFGF: basic fibroblast growth factor  
BM: bone marrow 
CAM: cell adhesion molecule 
CFA: complete Freund’s adjuvant 
CMV: cytomegalovirus 
CNS: central nervous system 
DNA: deoxyribonucleic acid 
EAE: experimental autoimmune encephalomyelitis 
ECM: extracellular matrix 
FACS: fluorescence activated cell sorting 
FCS: fetal calf serum 
FITC: fluoro-isothiocyanate 
GA: glatiramer acetate 
GAPDH: glyseraldehyde-3-phosphate dehydrogenase  
GDNF: glial-cell-line-derived neurotrophic factor  
GFP: green fluorescence protein 
HSC: hematopoietic stem cells 
IFN-γ: interferon-γ  
IL-1ß: interleukin-1ß 
MCA: middle cerebral artery 
MBP: myelin basic protein 
MOG: myelin oligodendrocyte glycoprotein 
MS: multiple sclerosis 
MSC: mesenchymal stem cells 
NGF: nerve growth factor  
NO: nitric oxide 
NSC: neuronal stem cells 
NT-3: neurotrophin-3 
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PBS: phosphate-buffered saline 
PCR: polymerase chain reaction 
PFA: paraformaldehyde 
PGK: phosphoglycerate-kinase 
PTX: pertussis toxin 
RNA: ribonucleic acid 
RT: reverse transcription 
SEM: standard error of the mean 
SCF: stem cell factor 
TBM: total bone marrow 
TGF-ß: transforming growth factor-ß  
TNF-α: tumor necrosis factor-α 
TPO: thrombopoietin 
VEGF: vascular endothelial growth factor  
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1. Introduction 
 
1.1. Multiple Sclerosis 
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the human 
central nervous system (CNS) affecting a large number of individuals in the Western 
countries, resulting in a debilitating paralysis and the loss of mental function 
(Steinman 1996; Hickey 1999; Noseworthy, Lucchinetti et al. 2000). 
 
1.1.1. Clinical aspects 
MS often begins in early adulthood with an autoimmune inflammatory strike against 
components of the myelin sheath. Sensory disturbances, lack of coordination and 
visual impairment are common features during the progression of the disease 
(Steinman 2001). 
In general terms, the course of the MS can be categorized into two main types as 
follows (Lublin and Reingold 1996): 
1) Relapsing-remitting. This is the most common form of MS. It generally occurs in 
younger people. The disease starts with an attack that lasts from days to weeks, 
followed by a remission period that can last months to years (when symptoms 
improve or disappear). Remission periods may be spontaneous or induced by 
immunosuppressive drugs and mostly alternate between a flare-up of symptoms and 
periods of deteriorating ability (figure 1.1.A).  
2) Chronic-progressive. Some MS patients enter in a second chronic phase of the 
disease characterized by the inability to walk which can lead to wheelchair 
confinement. About 20% of MS patients (usually those whose first symptoms occur 
after age 45) present as chronic-progressive without first developing relapsing-
remitting MS. Although this chronic-progressive type follows a downhill course, its 
severity varies widely. Therefore, three variants have been proposed to better describe 
it: 
2a) Secondary-Progressive. About half of the patients with relapsing-remitting MS 
develop secondary-progressive MS. Clinically it follows a course of progressive nerve 
and muscle deterioration with occasional acute flare-ups, remissions, and plateaus 
(figure 1.1.B).  
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2b) Progressive-Relapsing. In this case, the severity of the disease symptoms increases 
constantly from the beginning accompanied by acute symptom flare-ups and 
continued deterioration between relapses. This is a very rare form of MS (figure 
1.1.C). 
2c) Primary-Progressive. In rare instances, clinical disabilities begin directly with a 
continuous and gradual deterioration without any remission or flare-up. It occasionally 
levels off, and minor recovery is even possible. This occurs in about 10% of patients, 
who tend to be older than average at the time of diagnosis (Hauser and Oksenberg 
2006); (www.reutershealth.com) (figure 1.1.D). 
 
 
 
 
 
Figure 1.1. Diagrammatic representation of disease 
severity over time for the different categories of Multiple 
Sclerosis.A) relapsing-remitting; B) secondary 
progressive; C) progressive relapsing and D) primary 
progressive. (Source: www.mult-sclerosis.org)  
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1.1.2. Disease initiation 
The exact events leading to the development of the MS disease are not clearly 
understood, but there are several molecular and cellular components described that 
may take part in the destructive cascade leading to myelin damage.  
The insult to myelin components is dependent on the activation of an autoimmune 
response. An ongoing discussion focuses on whether this inflammatory reaction is 
first initiated within the immune system confines or in response to primary events 
impacting neuronal cells (Prat and Antel 2005).  
Accounting for the first possibility, a long favored hypothesis for MS initiation 
implicates that auto-reactive T cells that are generated in the systemic compartment 
gain later on access and persist in the CNS parenchyma, inducing the inflammatory 
phase of the disease. The main question still present is how exactly these T cells could 
have been activated for the very first time. It must be considered that a contact 
between antigen and cells must exist prior to their activation. Moreover, under normal 
conditions, T cells reacting against a self-antigen, are eliminated by programmed cell 
death. 
To explain how a potential immunogenic antigen can be originated in the CNS and 
later come in contact with T cells, the main detrimental cell population acting in MS, 
Walker et al proposed three hypotheses. The first one claims that a certain antigen can 
be captured in the brain by a dendritic (professional antigen presenting) cell and after 
the migration of this cell type to the lymph nodes, may initiate an immune response in 
the periphery. Secondly, they speculate about the idea of the drainage of soluble or 
particulate antigenic material, or alternatively, the transportation to the lymph nodes 
of the antigen by other cell types which are not a dendritic type (Walker, Calzascia et 
al. 2003). 
 
Respect to events primary affecting neuronal cells, there are speculations that acquired 
acute or persistent infections of these cells could result in tissue antigen release or 
alternatively that certain viral infections could be connected with the aetiology of MS 
by molecular mimicry responses. This is the case described for the MS-associated 
retrovirus (MSRV) (Perron, Garson et al. 1997). MSRV viral particles displayed pro-
inflammatory activities both in vitro, in human mononuclear cell cultures and in vivo, 
in a severe combined immunodeficient (SCID) humanized mouse model (Nowak, 
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Januszkiewicz et al. 2003). For instance, a study showed how the surface unit of the 
MSRV envelope protein specifically induced human monocytes to produce major 
proinflammatory cytokines. Even more, this surface protein could also trigger the 
maturation process of dendritic cells able to support a Th1-like type of T helper cell 
differentiation which are the main cell type involved in proinflammatory diseases as 
MS (Rolland, Jouvin-Marche et al. 2006). 
 
Factors believed to influence the very first stage of MS range from environmental to 
genetic background. With respect to the genetic contribution to MS aetiology, it is 
now believed that the genetic background of a patient might determine the disease 
susceptibility to a certain extent. The histocompatibility human leukocyte antigen-D 
(HLA-DRB1) gene is the strongest genetic factor identified so far which influences 
MS susceptibility (Herrera and Ebers 2003; Dyment, Herrera et al. 2005; Oksenberg 
and Barcellos 2005). Although until now the exact mechanism by this gene influences 
susceptibility to MS remain undefined but it is thought to be related with the gene 
product physiological function in immune responses.  
In summary, it is clear that there is not a unique cause of MS initiation. Triggering of 
MS pathology can be considered as an imbalance between immune and CNS 
homeostasis. 
 
1.1.3. Molecular pathogenesis 
Whereas the mechanisms proposed for the initiation of the immune response in the 
CNS in MS are still hypothetical, more direct data detailing the consequent effector 
stage of the disease is available. Current evidence indicates that in this inflammatory 
neurodegenerative disorder both, adaptive and innate immunity, play a relevant role, 
not only in initiation, but also in the progression of the disease (Imitola, Chitnis et al. 
2006). 
 
Regardless of their location and means of activation, lymphocytes must be specifically 
recruited to the CNS for development of the MS pathology. Initially, circulating 
immune cells penetrate the blood brain-barrier (BBB), which normally strongly 
regulates cell passage, by a process called transmigration, that proceeds according to 
the multi-step model described elsewhere for cell homing (Mackay 1991; von Andrian 
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and Mackay 2000). Briefly, in the initial step, “tethering”, low affinity bonds between 
Selectins (on the endothelial cell surface) and oligosaccharides (on the immune cells) 
reduce the velocity of the T cells to a rolling motion. At the same time, endothelial 
cells are induced to express Vascular Cell Adhesion Molecule (V-CAM) and class II 
Major Histocompatibility Complex (MHC) by Interferon (IFN)-γ and Tumor Necrosis 
Factor (TNF)-α released during the inflammatory response by T cells and 
macrophages. The final step is called “diapedesis” and consists in the passage of the 
immune cells into the extracellular matrix (ECM). This last step is mediated by 
Integrins, in particular α4β1 (Very Late Antigen (VLA)-4), α4β7, lymphocyte 
function-associated antigen (LFA)-1 on the T cells and Intercellular Cell Adhesion 
Molecule (I-CAM), V-CAM on the endothelial cells.  
Once the activated lymphocytes have extravasated from the blood vessels, they must 
migrate through an ECM composed mainly of collagen type IV. The α1 integrin 
subunit plays a relevant role in this binding to the matrix. Also, secretion of several 
matrix metalloproteases by the lymphocytes allows the access of these cells to the 
white matter surrounding the axons (Steinman, Martin et al. 2002). 
The encephalitogenic T cell response directed against different CNS antigens not only 
determines the lesional topography of CNS inflammation but also the composition of 
the inflammatory infiltrates (Schmidt 1999). 
 
In the past few years evidence derived from studies of anti-myelin antibodies (Abs) in 
CNS lesions of patients with early MS and of MS animal models has led to a renewed 
interest in the role for B cells, plasma cells and their products in the pathogenesis of 
MS in addition to that of T cells (Ziemssen and Ziemssen 2005). 
 
At the effector phase, when activated immune cells homed already to the CNS, many 
molecules are involved in final myelin damage and consequent progression of MS. 
Abs against myelin components are secreted (Burgoon, Gilden et al. 2004). 
Complement proteins are activated into a cascade that culminates in membrane attack 
complexes. Cytokines secreted by activated T cells, including TNF-α and 
lymphotoxin, have an effect on infiltrating macrophages as well as microglia and 
astrocytes. Concomitantly, damaged cells produce nitric oxide (NO) and osteopontin. 
The combined effect of abs, complement, NO and cytokines damages the myelin and 
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induces the macrophages to phagocyte large pieces of myelin sheath (Steinman, 
Martin et al. 2002) (figure 1.2). 
 
 
Figure 1.2.General scheme of MS molecular pathogenesis. T and B cells home to the 
CNS after adhesion molecule up-regulation. Cells encountering an antigen presenting 
cell release inflammatory cytokines. Demyelination mediated by combined action of 
Abs, complement and macrophages takes place. (From Steinman 2001. Nat. 
Immunol.). 
 
 
1.1.4. Current therapy 
Current treatments are most effective in the inflammatory phase of the disease and 
aim to interfere with the many stages of the immune cascade. However, recent 
evidence has emerged that inflammation may not only be destructive, but may also 
play a role in tissue repair (Hohlfeld, Kerschensteiner et al. 2006), which makes 
difficult the task of finding a suitable specific treatment.  
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Glatiramer acetate (GA; Copaxone, also known as Copolymer 1 or Cop-1), a 
copolymer of amino acids, has been very effective in the suppression of Experimental 
Autoimmune Encephalomyelitis (EAE), the animal model for MS. The 
immunological cross-reaction between the myelin basic protein (MBP) and GA serves 
as the basis for the suppressive activity of GA, by the induction of antigen-specific 
suppressor cells. The mode of action of GA consists of strong promiscuous binding to 
MHC class II molecules and competition with MBP and other myelin proteins 
(Aharoni, Teitelbaum et al. 1999). Suppressor T cells induced by GA are of the Th2 
type. Clinical trials with GA, both, phase II and phase III, were performed in 
relapsing-remitting MS patients, and demonstrated efficacy in reducing the relapse 
rate, decreasing magnetic resonance imaging (MRI)-assessed disease activity and 
burden and slowing progression of disability (Aharoni, Meshorer et al. 2002; Arnon 
and Sela 2003). After successful clinical trials this GA drug is currently available on 
the market. 
Another commonly used therapeutic agent is the β-IFN in its recombinant form 
specially to control the relapsing-remitting form of MS. The known effects are its 
interference with lymphocyte migration and other pleiotropic actions (Steinman 
2001). It is pertinent to notice that inhibitors and regulators of many of the above 
described molecules that take part in the steps of its molecular pathogenesis (e.g. cell 
adhesion, diapedesis, migration through ECM) are been tested as possible therapies 
for MS.  
Ideally, treatment might be feasible when a combination of more than one specific 
target could be assessed for each particular MS case. Further increases in the 
understanding of the pathogenesis of the MS are likely to assist in the identification of 
new targets for disease-modifying therapies. 
 
1.1.5. Experimental Autoimmune Encephalomyelitis (EAE) 
Many animal models of CNS demyelination have been described, reflecting the 
diversity of clinical manifestations in humans. EAE is the most frequently studied 
autoimmune model for MS. Although it does not exactly replicate the human 
counterpart, it shares many similarities and has provided valuable insights into the 
pathobiology of the disease (Ercolini and Miller 2006). 
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1.1.5.1. EAE induction 
EAE can be induced in a number of species, including rodents and non-human 
primates through experimental immunization with whole myelin proteins or specific 
myelin peptides in adjuvant. Alternatively, EAE can also be induced through systemic 
transfer of primed immune cells (Owens, Wekerle et al. 2001). 
In the 1930’s, EAE was initially developed to study episodes of paralysis occurring 
with certain vaccinations. Rivers and collaborators established this model in primates 
and their work was first published in 1933 (Rivers et al, 1933). More than seventy 
years had passed and many refinements and variations of the EAE forms have been 
developed including models for relapsing-remitting (Brown and McFarlin 1981) and 
progressive forms of MS (Lublin, Maurer et al. 1981).  
 
To induce the disease in mice (and other animals as well), immunization was initially 
made with whole spinal cord homogenate (Yasuda, Tsumita et al. 1975; Mitsuzawa 
and Yasuda 1976; Mitsuzawa, Yasuda et al. 1981). Now it is more clear which myelin 
epitopes are specifically capable of inducing EAE, for example, with respect to the 
strain of mouse used. Currently, peptides derived from the myelin as proteolipid 
protein (PLP), MBP or myelin oligodendrocyte glycoprotein (MOG) are used to 
induce EAE. For the present work, a twenty-aminoacid-immunogenic peptide which is 
a portion of the MOG molecule (aa 35-55) was chosen.  
Additionally, EAE induction depends on the inclusion of complete Freund’s adjuvant 
containing heat-killed mycobacteria (Billiau and Matthys 2001) providing a chronic 
inflammatory stimuli (Mitsuzawa and Yasuda 1976; Mitsuzawa, Yasuda et al. 1981), 
and also pertussis toxin (PTX) as adjuvant and disrupter of the BBB. A recent study 
shows that PTX could use Toll-like receptor 4 signalling to mediate its disease-
inducing effect (Kerfoot, Long et al. 2004; Racke, Hu et al. 2005). 
 
1.1.5.2. Molecular and cellular pathogenesis of EAE  
In the C57BL/6 (H-2b) mouse strain, EAE induced by MOG35-55 is characterized by 
early (around day 12 post-induction) acute paralysis, followed by a sustained chronic 
clinical course that gradually stabilizes. Extensive inflammation and demyelination 
coincide with clinical signs of disease.  
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As is the case in MS, chemokines and chemokine-receptors are critical in establishing 
a chemotactic gradient to recruit immune cells to the sites of inflammation in the 
CNS. Chemokines like IFN-γ-induced protein (IP)-10, Monocyte Chemoattractant 
Protein (MCP)-1 and RANTES are described to appear with the onset of the EAE 
symptoms (Elhofy, Kennedy et al. 2002).  
Like MS, EAE was classically considered a prototypic T-cell mediated animal model. 
It is characterized by infiltration of mononuclear cells into the CNS (Fuller, Olson et 
al. 2004). This disease was viewed in terms of type 1 versus type 2 immunity: the type 
1 cytokines IFN-γ and TNF-α promoting disease (Renno, Krakowski et al. 1995), 
whereas an IL-4-dominated, type 2 response being protective. For instance, it was 
observed that the adoptive transfer of Th1 clones could induce the disease (Zamvil, 
Nelson et al. 1985). Although a regulatory role for IFN-γ in EAE has been shown, 
acting on T cell proliferation and directing chemokine production, with profound 
implications for the onset and progression of the disease (Tran, Prince et al. 2000), 
contrasting observations were made in mice lacking Th1 associated molecules as IFN-
γ (Ferber, Brocke et al. 1996), IFN-γ receptor and IL-12 receptor as well as IL-12p35 
(Becher, Durell et al. 2002) that unexpectedly developed severe EAE as well. 
Therefore, the initial idea of an exclusively Th1 phenotype accounting for the EAE 
(and MS) degeneration has been challenged. 
 
In a detailed study using a sensitive single-cell based assay Juedes et al. determined 
that the MOG immunization resulted in the priming of both Th1 (lymphotoxin, IFN-γ, 
and TNF-α) as well as Th2 (IL-4) cells in the spleen. Only 7 days after immunization 
IFN-γ, and TNF-α producing CD4 Th1 cells seemed to be present in the CNS, peaked 
at day 20, and then waned. At this time points, microglia as well as infiltrating 
macrophages were additionally responsible for the production of TNF-α (Juedes, 
Hjelmstrom et al. 2000). 
More recent data point to important roles for IL-23 and IL-6 (rather than IL-12 and 
IFN-γ) in the establishment and persistence of the inflammatory lesion (Langrish, 
Chen et al. 2005). Moreover, therapeutic approaches with anti-IL-23 or anti-IL6 
antibodies could ameliorate EAE (Chen, Langrish et al. 2006), and IL-6 knock out 
mice showed resistance to EAE (Samoilova, Horton et al. 1998). 
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On the other hand, IL-10 appears to be the dominant cytokine mediating recovery. 
The source of IL-10 includes B cells (most probably in the peripheral lymphoid 
organs). However, the key IL-10-producing cell within the CNS is a CD4+CD25+ T 
cell population that has regulatory function and is critical for the resolution of the 
disease (Samoilova, Horton et al. 1998; McGeachy and Anderton 2005). 
In the monophasic and relapsing-remitting forms, recovery from the disease is also 
associated with clearance of inflammatory infiltrates from the CNS. 
 
 
1.2. Cerebral ischemia 
Acute ischemic stroke caused by cerebral artery occlusion leading to infarction of brain 
tissue and loss of neuronal cells is a serious vascular CNS disorder and it represents a 
leading cause of death and disability in industrial nations (Haas, Weidner et al. 2005). 
 
1.2.1. Clinical aspects and molecular pathology 
Clinical manifestations of transient ischemic attack include: motor dysfunction, sensory 
alterations, speech or language disturbance and loss of vision. 
After an ischemic event an inflammatory response in the brain tissue is elicited (del 
Zoppo, Ginis et al. 2000). Inflammatory interactions between endothelial cells and 
leukocytes occur at the BBB level involving cytokines, adhesion molecules, 
chemokines. These interactions are critical to the pathogenesis of tissue damage in 
cerebral infarction (Huang, Upadhyay et al. 2006). 
At the molecular level, ischemia results in rapid loss of high-energy phosphate 
compounds and generalized depolarization, which induces release of glutamate and, in 
selectively vulnerable neurons, opening of both voltage-dependent and glutamate-
regulated calcium channels. This allows a large increase in cytosolic Ca(2+) and 
consequent activation of mu-calpain, calcineurin, and phospholipases with proteolysis 
of calpain substrates, activation of nitric oxide synthase (NOS), and accumulation of 
free arachidonic acid, which can induce depletion of Ca(2+) from the intracellular 
storage compartment.  
A kinase that shuts off translation initiation by phosphorylating the initiation factor-2 
(eIF)-2α is activated. Early during reperfusion, oxidative metabolism of arachidonate 
causes a burst of excess oxygen radicals, iron is released from storage proteins, and NO 
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is generated. Neurons present then altered translation initiation mechanisms that reduce 
total protein synthesis, and down-regulate survival signal-transduction together with 
caspase activation leading to programmed cell death (White, Sullivan et al. 2000). 
 
1.2.2. Middle cerebral artery occlusion as a model of cerebral ischemia 
Animal models of cerebral infarction are crucial to understand the molecular and 
cellular mechanisms following ischemic brain injury and to the development of 
therapeutic interventions for victims of all types of stroke.  
Rodents have been used extensively in such research. First established in rats, the 
middle cerebral artery occlusion (MCAO) as a model for focal cerebral ischemia, has 
been well accepted as it has shown to be reproducible and to reflect the human clinical 
settings (Ginsberg and Busto 1989). Since the development of an endovascular 
method published in 1989, MCAO has been applied commonly in rats and because of 
technical demands and issues with survival, relatively few laboratories have taken 
advantage from the MCAO method in the mouse (Duckworth, Butler et al. 2005). 
 
 
1.3. Neurotrophins 
Neurotrophins are a family of structurally related genes whose products have been 
attributed to have an important role in the regulation and homeostasis of the central 
and peripheral nervous systems.  
 
The first neurotrophin to be described was the nerve growth factor (NGF), followed 
by the brain derived neurotrophic factor (BDNF). Structural analysis of these two 
proteins revealed more than 50% of homology and led to the search for more members 
of the survival factor family. Thereafter, several members were discovered in a rapid 
succession: Neurotrophin (NT)-3, NT-4/5 and NT-6 (Shen, Figurov et al. 1997). 
In parallel to the discovery of neurotrophic factors, a family of high affinity receptors 
called TrK (Tyrosine Kinases related) has been characterized. The first one described, 
TrK A, was isolated from carcinoma cells, and initially was identified as a proto-
oncogene. This receptor binds with high affinity to NGF (Lewin 1996; Lewin and 
Barde 1996). 
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Later, TrK B, a second member, was found to be functional when BDNF and NT-4/5 
bind to it, explaining the similar patterns of biological effects observed for these two 
neurotrophins (Klein et al., 1991a, 1991b). The last member to be isolated was the 
TrK C, the receptor for NT-3 (Lamballe, Smeyne et al. 1994). Neurotrophins can also 
bind to a low affinity receptor, p75 and trigger apoptosis (Ibanez 1994). 
It was originally thought that neurotrophin receptors were strictly located along the 
nervous tissue, but several studies have reported their expression in a wide range of 
cell types including: muscular (Ochi, Saito et al. 1997), cardiac (Donovan, Hahn et al. 
1996), lymphoid (Labouyrie, Parrens et al. 1997), endothelial (Ricci, Greco et al. 
2000; Ricci, Greco et al. 2001), bone marrow (BM) tissue (Labouyrie, Dubus et al. 
1999) and B cells (Kerschensteiner, Gallmeier et al. 1999). It still remains unclear 
under which conditions the effects mediated by these receptors are considerable in 
regard to each particular cell type. 
 
It is therefore important to notice that the biological action of these neurotrophic 
factors is not tissue restricted but they also exert many pleiotropic effects. Some 
examples are augmentation of microvascular endothelial cell proliferation and 
expression of adhesion molecules (Raychaudhuri, Raychaudhuri et al. 2001), 
inhibition of monocyte migration through the BBB (Flugel, Matsumuro et al. 2001), 
promotion of neutrophil survival (Kannan, Usami et al. 1992) and in vitro migration 
of muscle cells (Donovan et al., 1995). 
Moreover, there is increasing evidence that these factors may play a major role in regulation 
of immune response. In fact, many neurotrophins and their receptors are produced and act in 
the immune system and therefore it appears likely that neurotrophins can mediate 
bidirectional cross-talk between the nervous and immune systems (Kerschensteiner, 
Stadelmann et al. 2003). 
 
1.3.1. Neuroprotection in neurodegenerative disorders 
Treatments of neurodegenerative diseases such as MS should take into account the 
heterogeneous pathophysiology of the disease.  Anti-inflammatory approaches have 
been proven to be a possible therapy for MS, but a current concept is to declare 
neuroprotection as an important goal in MS therapy. Neuroprotective strategies in MS 
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could focus on rescuing degenerating axons, e.g., by reinforcing endogenous 
neurotrophic action (Kerschensteiner, Stadelmann et al. 2003). 
Addressing the neurodegenerative component of the MS disease is an important 
objective of the treatment, since axonal injury is believed to underlie the accumulation 
of disability and disease progression. Specific treatment strategies to prevent 
neurodegeneration need to be developed acting within the CNS. A promising 
approach is to enhance neuroprotective immunity inside the brain, believed to be 
mediated, at least in part, by the release of neurotrophic factors within the CNS from 
infiltrating immune cells (Ziemssen 2005). 
Many authors are in favor of the idea of a dual effect of the attacking immune cells, 
from one hand conferring damage to the neuronal environment, but from the other, 
mediating protection by production of trophic factors.  
Fewer endogenous neurotrophins are present in older, chronic MS plaques (areas of 
brain tissue scarring and damage) than in the early stages of lesion development. A 
reasonable strategy for slowing axonal degeneration in this late phase of MS, which is 
notoriously resistant to other forms of therapy, would be to provide exogenous 
(therapeutic) neurotrophic support (Hohlfeld, Kerschensteiner et al. 2006). 
Regarding the influence that some neurotrophic factors may have during MS, a 
clinical study performed by Cagguilla et al. observed the correlation between grade of 
MS and production of several neurotrophic factors, including NT-3 in peripheral 
blood mononuclear cells. They found increased levels of glial-cell-line-derived 
neurotrophic factor (GDNF), NGF and NT-3 growth factors in the post-relapse phase 
in patients with complete remission (Caggiula, Batocchi et al. 2005). In another study, 
BDNF and its truncated receptor gp145TrKB were found to be present in MS lesions. 
The number of BDNF reactivity correlated with the lesional demyelinating activity, 
and the authors suggested a role for some neuronal growth factors not only under 
normal conditions but also under pathological conditions (Stadelmann, 
Kerschensteiner et al. 2002). 
 
With respect to the significance of providing trophic support in neurodegenerative 
cases, Lu et al. have shown functional recovery in a rat model of spinal cord injury 
upon locally or delivered administration of neurotrophins. When a combinatorial 
therapeutic approach was used, NT-3 and cAMP contributed to a clear axonal 
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regeneration beyond spinal cord injury in a strategy designed to enhance spinal cord 
repair (Lu, Yang et al. 2004).  
Neuronal stem cells (NSC) expressing neurotrophic factor genes grafted in vivo to 
cystic dorsal column lesions in the cervical spinal cord of adult rats and supported 
extensive growth of host axons. Moreover, these NSC were genetically modified to 
produce NT-3. In this case, effects of NSC on host axons were enhanced. Thus, it has 
been demonstrated for this particular paradigm of spinal cord injury that NSC can 
promote host neural repair by secreting intrinsic growth factors, and their 
regeneration-promoting activities can be modified by neurotrophic gene delivery (Lu, 
Jones et al. 2003). 
Locally injection of fibroblasts also modified to express human NT-3 directly into 
spinal cord lesions was able to elicit growth of corticospinal axons in chronic stages of 
injury and improved functional outcome compared to non-growth-factor-treated 
animals (Tuszynski, Grill et al. 2003). A similar outcome was shown for human 
BDNF expressing mesenchymal stem cells (MSC) in the same animal model (Lu, 
Jones et al. 2005). Furthermore, in another study it was shown that the co-graft of NT-
3 expressing Schwann cells and NSC enhanced neuronal survival in a rat model of 
spinal cord injury (Guo, Zeng et al. 2006). 
Flugel et al. showed in cell transfer studies that MBP-specific CD4 cells modified to 
express NGF were unable to mediate clinical EAE alone or in combination with non-
transduced MBP specific cells. This was associated with a reduced inflammation in 
the CNS and they propose an impaired monocyte migration through the BBB as a 
putative mechanism (Flugel, Matsumuro et al. 2001). 
All these data indicate that a combination of cell and trophic support could be 
considered a suitable approach for recovery of degenerating neuronal tissue. 
Moreover, effects of neurotrophic factors could be extended beyond nervous tissue 
when taking into account their influence on the immune system. 
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1.4. Hematopoietic stem cells 
1.4.1. Terminology: stem cells, precursor cells and progenitor cells 
By definition, a stem cell is an undifferentiated cell that produces daughter cell which 
can either remain as a stem cell (self-renewal) or commit to a pathway leading to 
differentiation. This pathway to differentiation usually involves the daughter 
becoming a precursor cell which proliferates prior to its differentiation. In general, the 
terms precursor cell and progenitor cell are used interchangeably.  
Mammalian stem cells can be classified according to their developmental potential. 
They are called either “totipotent”, in the case that they can produce all embryonic and 
extra-embryonic tissues required for development, or “pluripotent” (as in the case of 
embryonic stem cells, which are derived in culture from epiblast cells), if they can 
give rise to all cells of the embryo proper.  
Adult stem cells present in the organs or tissues of adult animals are considered 
“multipotent” if they are able to differentiate into more than one cell type. 
Alternatively, they are called “unipotent” when they are able to contribute only to one 
mature cell type. Hematopoietic, hepatic, and neuronal stem cells belong to the 
multipotent category (Raff 2003). 
 
1.4.2. Ontogenesis of hematopoietic stem cells 
Hematopoietic stem cells (HSC) are at the foundation of the hematopoietic hierarchy 
and give rise to all blood lineages in the adult organism. In the early embryonic state 
of all vertebrates, HSC appear to derive from hemangioblasts, which are common 
progenitors with the precursors of blood vessels (Dieterlen-Lievre, Pardanaud et al. 
2002; Bollerot, Pouget et al. 2005). These hemangioblastic cells condense into 
aggregates that are called blood islands. The inner cells of these blood islands become 
HSC, while the outer cells become angioblasts, the precursors of the blood vessels 
(Choi, Kennedy et al. 1998; Jaffredo, Nottingham et al. 2005) (figure 1.3). 
Moreover, many proteins as stem cell leukemia (SCL), a basic helix-loop-helix 
transcription factor (Chung, Zhang et al. 2002) and Flk-1, a receptor tyrosine kinase, 
(Schuh, Faloon et al. 1999) are shared by the earliest blood and capillary cells. Also, 
the transmembrane cell surface glycoprotein CD34 has been described to be expressed 
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in both, hematopoietic and vascular immature cells (Wood, May et al. 1997; Choi 
1998). 
 
 
Figure 1.3. Early formation of hematopoietic stem cells and endothelia. Both cell types derive 
from a common hemangioblast progenitor. A) In the wall of the yolk sac, mesenchymal cells 
condense. B) Condensed cells form angiogenic clusters. C) Centre of cluster cells form blood 
cells and outside located cells originate vessel endothelial cells. (Source: Gilbert, S. 
Developmental Biology. 6th Edition. Sinauer Associates, Inc. 2000).  
 
In murine and human systems, embryonic and fetal development is associated with 
multiple switching in the sites of hematopoiesis. The phenomenon is initially extra-
embryonic, occurring in the blood islands of the yolk sac. There, erythropoiesis takes 
place and it proceeds synchronously and may be erythropoietin-insensitive, at the 
same time the yolk sac milieu is not permissive to the development of other cell lines. 
The final products of hematopoiesis at this stage are nucleated red blood cells. Yolk 
sac hematopoiesis is considered a primitive (as compared to definitive) form of 
hematopoiesis (Tavassoli 1991).  
HSC later on seem to migrate via the bloodstream to the liver and spleen to seed these 
tissues, which then carry the burden of hematopoiesis until birth and for some time 
thereafter. Here some granulopoiesis also occurs, in addition to erythropoiesis. 
Hematopoiesis is progressively in its definitive form, lacking synchronicity of cell 
growth with the end red blood cell being enucleated and synthesized hemoglobin of 
the adult type.  
 
In an adult organism, blood cells originate from the BM and spleen, and are 
predominantly granulopoietic (Zanjani, Ascensao et al. 1993). In all cases, recognition 
and binding of HSC to lineage specific stromal cells present in these hematopoietic 
tissues is called "homing", and initiates the processes of differentiation, proliferation, 
and maturation of HSC (Konno, Hardy et al. 1990). The homing mechanism is 
A B C
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mediated by a lectin-glycoconjugate interaction. The lectin is on the surface of HSC 
and progenitor cells with specificity for galactosyl and mannosyl residues on the 
stromal cells. The binding is subsequently stabilized by membrane-bound 
proteoglycans, integrin-like receptors, and fibronectin and it is crucial for a proper 
stem cell maintenance and maturation (Tavassoli 1991; Tavassoli 1994). 
 
1.4.3. Adult bone marrow derived stem cells 
BM is the tissue present in the core of almost all long bones of adult mammals and 
contains an heterogeneous mixture of mature and maturing precursors of endothelial, 
hematopoietic and mesenchymal cells (Wang, Pierce et al. 2005). The BM derived 
HSC differentiate into all mature blood cells. The BM derived endothelial progenitors 
cells will give rise to vascular cells, and the BM derived stromal cells, called also 
mesenchymal stem cells (MSC), can differentiate into mature cells of multiple tissues 
including fat, bone and cartilage (Herzog, Chai et al. 2003). 
 
HSC are currently the best characterized multipotent stem cell population and were 
initially isolated from mouse BM in 1988 (Spangrude, Heimfeld et al. 1988). The 
ability to recover hematopoietic function by repopulating all lineages comprising the 
entire blood system of a myeloablated organism functionally defines mammalian HSC 
(Bhatia 2003). Therefore, distinguishing features of HSC for reconstitution are the 
requirement of homing to their niche in the BM, extensive self-renewal, and their 
differentiation into all mature blood cell types (schematically represented in figure 
1.4).  
 
Studies emphasize the heterogeneity of the HSC compartment, in terms of 
proliferation and self-renewal capacities. Currently, there are two classes of mouse 
HSC that can be distinguished on the basis of cell-surface markers and potential for 
self-renewal: the long term (LT) repopulating cells can reconstitute the blood system 
of an irradiated mouse for its lifetime, alternatively the short-term (ST)-HSC can do so 
only for six weeks.  
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Figure 1.4. Hematopoietic stem cells give rise to all mature blood and immune cells 
and are able to self-renew. (Source: stemcells.nih.gov) 
 
Upon transplantation in a myeloid cell ablated mouse, it was shown that LT 
repopulating cells remain quiescent in the BM shortly after engraftment, whereas ST-
HSC are more rapidly dividing (Neben, Redfearn et al. 1991). 
Lanzkron and collaborators observed that transplanted HSC homed normally to spleen 
and BM. Nevertheless, only cells in this last tissue, were significantly more competent 
at reconstituting lethally irradiated secondary hosts, suggesting BM to be the niche of 
the LT-HSC (Lanzkron, Collector et al. 1999a; Lanzkron, Collector et al. 1999b). 
 
A central issue of the HSC biology is to understand the mechanisms behind the 
regulation of their self-renewal and differentiation as any miss regulation of these 
processes can be the cause of uncontrolled cell growth and even leukemia.  
After isolation from adult mice, it was calculated that around 8% of the LT-HSC 
entered the cell cycle per day (Cheshier, Morrison et al. 1999). The HSC cell cycle is 
tightly regulated by external factors such as cytokines and interactions with stromal 
cells and extra-cellular matrix in the BM microenvironment.  
Many groups have implicated the interaction between osteoblasts (bone-forming cells) 
as the one of the key regulatory components of the HSC microenvironment in the BM. 
Moreover, contact between Tie2 receptor in HSC and Angiopoietin-1 produced by 
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osteoblasts was shown to maintain the LT repopulating activity of HSC (Arai, Hirao et 
al. 2004). 
Intrinsic transcription factors as c-Myb, GATA-2, HOX family proteins (Miyake, 
Brun et al. 2006) and Bmi-1 (Park, Qian et al. 2003) were described to contribute to 
the maintenance of adult self-renewal of HSC and up to 70% of HSC exhibited 
detectable levels of telomerase activity associated also with this renewal feature 
(Morrison, Prowse et al. 1996). On the other hand, cell cycle regulators as p21 and 
p27 proteins are known to maintain quiescence in these HSC (Ezoe, Matsumura et al. 
2004).  
 
In the mouse, LT-HSC make up approximately 0.007% of whole BM and are 
characterized by their undetectable levels of lineage markers (i.e. B220, CD3, Mac-1, 
TER-119 and Gr-1), double c-Kit and Sca-1 expression, and low levels of Thy-1 
(Morrison, Uchida et al. 1995). The ability to efflux the vital dye Hoescht 33342 is 
also a feature described for these cells (Jackson, Majka et al. 2002) known as side 
population, when analyzed by flow cytometry. 
There is a current concept of “aging of stem cells” that implies the loss of their self-
renewal capacity upon successive transplantation or if they are obtained from an older 
organism (Morrison, Wandycz et al. 1996; Liang, Van Zant et al. 2005). However, 
this concept has been challenged by groups showing no stem cell exhaustion after 
serial transplantations and arguing that instead, extrinsic mechanisms that may affect 
this aging effects are reversible by administration of exogenous cytokines (Iscove and 
Nawa 1997; Benveniste, Cantin et al. 2003). 
 
1.4.4. Culture of adult hematopoietic stem cells  
The possibility of keeping and expanding HSC in vitro would contribute not only to 
the better understanding of their biology, but also to their genetic manipulation and 
further use in therapy approaches. Nevertheless, culture and expansion of HSC in vitro 
has been demonstrated not to be an easy challenge. Once they are extracted from their 
BM niche, HSC are very prone to lose their pluripotency. 
The most commonly used stimulating cytokines in HSC culture are thrombopoietin 
(TPO), Stem Cell Factor (SCF) and IL-6. In general they all promote self-renewal and 
expansion, and they are used in particular when these cells are genetically modified by 
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retroviruses. Also the use of the HOXB4 transcription factor has been shown to be 
highly effective in the HSC expansion, specially of human origin, in vitro when used 
as a protein able to translocate through the HSC membrane (Amsellem, Pflumio et al. 
2003; Miyake, Brun et al. 2006). 
Expansion in vitro of HSC (in particular human type) is a major challenge in cellular 
therapy, and the development of cell amplification factors is being widely considered. 
 
1.4.5. Migration of bone marrow derived cells into the central nervous system 
A classical thought was that HSC derived from BM, after undergoing differentiation, 
would exclusively give rise to circulating immune and red blood cells, throughout 
adulthood. Alternatively, it was thought that stromal progenitors from BM would only 
differentiate into structural cells such as chondrocytes or osteocytes. In the year 2000 
this perspective of a limited differentiation capability of these BM cells began to 
change after Mezey and collaborators (Mezey, Chandross et al. 2000) and Brazelton 
and collaborators (Brazelton, Rossi et al. 2000) described the migration of BM cells to 
the CNS, further showing the expression in these BM derived cells of neuronal 
markers once in the brain region. 
Since then, recent publications have mentioned the migration of BM cells into CNS 
and their establishment as resident microglia (Eglitis and Mezey 1997; Ono, 
Yoshihara et al. 2003; Asheuer, Pflumio et al. 2004); and possibly neurons (Priller, 
Persons et al. 2001). 
This group of publications have generated enthusiasm in the cell therapy field, in 
respect to the possibility of using stem cells or their derivatives for therapy of 
neurodegenerative disorders.  
 
1.4.6. Plasticity versus cell fusion of adult bone marrow derived stem cells 
There is indeed controversy about the fate of these BM cells once in the CNS 
environment. While publications claimed that cells coming from BM after 
transplantation to maintain their hematopoietic phenotype once they migrated to the 
brain (Ono, Yoshihara et al. 2003; Massengale, Wagers et al. 2005), others challenged 
the initial idea of trans-differentiation of BM cells with studies that demonstrated the 
existence of spontaneous cell fusion events between BM and resident neuronal cell as 
the cause of fate-switch (Terada, Hamazaki et al. 2002; Alvarez-Dolado, Pardal et al. 
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2003). Differences in experimental conditions and BM cell population used in each 
study may account for the cell fate (or fusion event) reported for the brain detected 
BM cells. At the same time, there are some points to be considered when claiming a 
cell plasticity case. For instance, which methods were used for final cell phenotype 
identification (staining and/or functional assays) and if a heterogeneous BM 
population was selected for the transplantation experiments. All these conditions may 
bring contradictory interpretations of the fate that the BM cells may have in the host 
tissue. 
 
However, the reported migration of BM derived cells towards the CNS and passage 
through the BBB and moreover, their eventual differentiation into resident microglia 
is a very attractive feature that can be taken into future consideration, in particular as 
means of transport of therapeutic molecules towards the CNS. 
1.4.7. Stem cell therapy for central nervous system disorders 
Many attempts have been made in recent years to interfere with degeneration 
occurring during the progression of CNS diseases. Recent studies have demonstrated 
the use of stem cells for effective treatment of experimental inflammatory diseases of 
the CNS. Among them, it has been described that NSC may be engrafted into the 
injured CNS, migrating to the inflamed areas, and can contribute to functional 
recovery and tissue repair through their differentiation in neuronal cells and the 
release of anti-inflammatory factors (Pluchino, Quattrini et al. 2003; Einstein, 
Grigoriadis et al. 2006).  
One of the major concerning points to overcome when using cell based therapy is the 
ethical issue surrounding stem cells, in particular when using (human) embryonic 
cells. Adult BM derived stem cells are regarded as promising tools in this respect. 
Moreover, they have the additional advantages such as avoidance of immune rejection 
(they can be obtained from the same patient), and reduced chance of tumor formation 
(which is a usual problem derived from the use of embryonic stem cells). 
 
Accounting for the possible therapeutic use of BM adult stem cells in MS, it was 
reported the administration of BM derived MSC into EAE induced in mice. It was 
shown that these cells ameliorated the course of the disease, if applied before disease 
appearance. A decrease in inflammation and demyelination in the CNS of animals 
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treated with BM-derived MSC could be observed. In vitro, BM cells inhibited T cell 
proliferation and decreased IFN-γ and TNF-α production. The authors concluded that 
the cells induce an unresponsive state of autoimmune T-cells (Zappia, Casazza et al. 
2005). 
In another report, human BM cells were also administered in the same animal model 
of MS and neurological function recovery was shown. The authors also observed a 
reduction in the inflammatory infiltrates and in the demyelination. At the same time, 
levels of BDNF were increased, possibly contributing to oligodendrocyte progenitor 
survival (Zhang, Li et al. 2005). 
 
The use of adult stem cells has also been reported in regard to other CNS insults as it 
is the case of cerebral ischemia. Following an ischemic insult, experimental 
transplantation of BM cells into irradiated recipient animals resulted in engraftment 
into the ischemic lesions, after stroke. BM derived cells migrated into the ischemic 
lesion and integrated into the peri-infarct zone to become microglial-like cell type. 
Moreover, the authors claim that the BM cells took part in a injured tissue repair 
process (Beck, Voswinckel et al. 2003).  
Therefore, much excitement has been generated over the possibility of using stem 
cells for the treatment of neurodegenerative disorders and many attempts are been 
made to find a suitable approach. Considering the source of cells and the ethical 
background adult stem cells present a clear advantage with respect to embryonic stem 
cells and to study possible applications of this cell type is a major goal to be achieved. 
 
 
1.5. Lentivirus based vector system 
The use of virus-derived vectors for cell genetic modification has opened innumerable 
perspectives since first developed. They have shown not only to be a powerful tool for 
the study of relevant molecules by gain/loss of function assays, but also in the field of 
gene therapy, for potential genetic treatment of many diseases. 
 
1.5.1. Introduction to Lentivirus  
The most common viral-derived vector used in preclinical research for gene therapy 
applications has its origin from the human immunodeficiency virus type-1 (HIV-1). 
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HIV-1 is a member of the retrovirus (Retroviridae) family of viruses. The main 
feature of this family is that their genome, an RNA molecule, is converted into a 
double stranded DNA molecule during replication. Within the subfamilies of the 
retroviruses, the lentivirinae is a group associated with slow and progressive diseases 
affecting the immune system. In fact, the term “Lenti” comes from slow in Latin, 
referring to its slow and persistent rate of infection. 
In general, lentiviruses such as the HIV-1 are considered to have a complex genome. 
In addition to structural genes like gag, pol and env, they contain a number of 
regulatory and accessory genes involved in the modulation of gene expression, 
assembly of viral particles and structural function alterations in the infected cells 
(Trono 1995). In total, six accessory genes: tat, rev, nef, vpr, vpu, and vif are 
implicated in the viral pathogenesis (Emerman and Malim 1998; Li, Li et al. 2005). 
The life cycle of the lentivirus is common to all members of the Retroviridae family 
and can be described by the following steps (schematically represented in figure 1.5): 
1- Attachment and entry: the interaction between the virus and the target cell occurs 
via specific receptors (on the cell membrane). Once bound to the surface, the viral and 
cellular membranes undergo fusion. After this fusion step, the virion nucleoprotein is 
delivered to the cell cytoplasm where reverse transcription begins.  
2- Reverse transcription: synthesis of double stranded DNA from an RNA template is 
carried out by the reverse transcriptase enzyme (present in the virion nucleoprotein) 
and uses cellular tRNA as a primer.  
3- Integration: once the viral DNA is synthesized, the integrase catalyzes its 
integration into the host genome and allows the provirus to become a permanent 
genomic element in the host. 
4-Transcription and viral protein synthesis: the first transcription products from the 
virus code for the REV TAT and NEF. In a late stage, un-spliced and single spliced 
RNA species are produced. 
5-Virion assembly and release: viral genome and structural proteins are packed into 
the viral particles and released at the plasma membrane.  
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Firgure 1.5. Schematic representation of a retrovirus life cycle which 
can be described in 5 steps from attachment of the virus to host cells till 
the new virion assembly and release.  
(Source: www.clontech.com/ expression/retro/images/retro2.gif). 
 
 
1.5.2. Lentivirus based gene transfer system 
The most attractive feature of a system for genetic engineering based on lentivirus is 
under no doubt the capability of this virus type to infect non-mitotic cells. This is in 
sharp contrast to their predecessors, the oncoretroviruses, which require cell cycling 
within hours for transfer of genes into host cells (Roe, Reynolds et al. 1993). 
Replication of HIV-1 in non-dividing and slowly proliferating cell populations 
depends on active import of the viral pre-integration complex (PIC) into the cell 
nucleus and it is commonly accepted that this complex hijacks the cellular nuclear 
import machinery to do so. Within the viral proteins known to play a role in the 
transport of HIV-1 through the nucleopore of the cell are present: “matrix”, “virion 
protein R” (VPR) (Bukrinsky and Adzhubei 1999) and “integrase” (Bukrinsky, 
Haggerty et al. 1993; Gallay, Hope et al. 1997). 
 
(1) 
(2) 
(3) 
(4) 
(5) 
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In general terms, the principle of the lentivirus derived system consists of the 
construction of replication-defective recombinant chimeric lentiviral particles from 
three different components: the genomic RNA, the internal structural and enzymatic 
proteins and the envelope glycoprotein. 
 
In the third generation of the vector system only three genomic RNA sequences from 
the HIV-1 are remaining (Dull, Zufferey et al. 1998). The viral genetic information 
contained in the vector is the only transferred to the host cells (not the accessory 
packaging plasmids) and represents only the 20% of the original viral genomic RNA. 
Removal from this vector of almost all original viral genes ensures that no potentially 
immunogenic proteins are expressed in target cells. Some cis-acting flanking 
sequences were left to ensure the proper packing of the coding cassette. The use of a 
long terminal repeat (LTR) enables transcription in the absence of tat. This LTR also 
contains a self-inactivating deletion for biosafety and it is detailed later. 
The vector system contains three trans-acting elements: gag and pol which encode for 
the structural and enzymatic components of the virion and rev for the transcriptional 
regulation necessary for correct gag and pol expression, rev is necessary to prevent 
splicing of the transfer vector RNA in the producer cell by exporting it out of the 
nucleus during viral production (Delenda 2004) (figure 1.6). 
 
Although several proteins can pseudotype lentiviral particles (Sandrin, Boson et al. 
2002), the G protein of the vesicular stomatitis virus G-(VSV) is the one most 
commonly used. This envelope protein binds to the phospholipids in the bilayer of the 
cytoplasmatic membrane in vertebrates and also invertebrates (Burns, Friedmann et al. 
1993), conferring a width range of host that can be infected. The G-VSV also allows 
to achieve high titers with unconcentrated viral particles and it is stable when 
ultraconcentrated and when frozen particles are required (Reiser 2000). 
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Figure 1.6. Scheme showing the features that were taken from the original HIV-1 genome and 
elements (middle) for the accessory plasmids (top) and the expression vector (bottom) in the 
third generation of lentivirus derived system. (Adapted from Salmon T. and Trono D. “Design 
and production of HIV-derived vectors”. Cell biology: a laboratory handbook, 3rd edition. 
Elsevier, 2005). 
 
 
CMV: cytomegalovirus promoter 
Gag/pol: structural proteins and enzymes  
for viral replication 
RSV: rous sarcoma virus promoter 
rev: transcriptional replication protein 
polyA: polyadenylation site  
U3-R-U5: HIV-1 long terminal repeat  
SD: major splice donor 
RRE: rev-responsive element 
Ψ: HIV-1 packaging signal for encapsidation of 
genomic RNA 
WPRE: Woodchuck Hepatitis Virus Post-
transcriptional Regulatory Element  
∆U3: self- inactivating deletion of the U3 part of 
the LTR : long terminal repeats 
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1.5.3. Lentivirus production and biosafety 
In order to generate replication-incompetent viruses, the vector containing the gene of 
interest is co-transfected into a packaging cell line together with the accessory 
plasmids which contain the virion packaging elements.  
The cell line of choice for viral particle production is the 293 line, which was derived 
from human embryonic kidney. Currently for our work we are using the 293 FT, 
where F stands for fast growing cells and T stands for large T antigen (this is the 
origin of replication). 
 
As it has its origin in one of the most deadly virus affecting human kind today, many 
issues concerning biosafety have emerged, but still researchers feel confident with the 
safety levels reached in lentiviral vectors, especially with the most recent (third) 
generation that even exceeds the safety standards of oncoretroviral vectors currently 
used in clinics (Trono 2000).  
In general terms, biosafety of a certain vector production system is achieved by 
distributing the coding sequences of its proteins and regulatory elements in as many 
independent units as possible. This is the case with the lentiviral system, where the 
system components were segregated into three helper plasmids. The Gag/pol 
accessory genes are supplied in trans, namely in a separated vector and are never 
packed into the viral particles.  
In addition, in the expression vector, the 3 prime LTR region has been deleted in the 
U3 region to remove all transcriptionally active sequences, creating a self-inactivating 
LTR, this means that once in the target cell the vectors lose the transcriptional 
capacity of their LTR (Miyoshi, Blomer et al. 1998; Zufferey, Dull et al. 1998). 
Finally, sequence overlap between vector and helper sequences has been reduced to 
less than 10 nucleotides which significant reduces the chance of an homologous 
recombination event to occur (Trono 2000). 
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1.5.4. Lentivirus derived vector applications 
There are many cell types described to be susceptible to lentivirus-derived vector 
transduction since the first study by Naldini et al. in 1996 showing stable gene 
modification  of non-dividing cells (Naldini, Blomer et al. 1996). The wide range of 
cell types shown to be transducible until now includes: epithelial cells (Johnson, Olsen 
et al. 2000), hepatocytes (VandenDriessche, Thorrez et al. 2002) and retinal cells 
(Miyoshi, Takahashi et al. 1997). Furthermore, efficient in vivo gene delivery and 
long-term expression in the CNS had been shown successfully (Naldini, Blomer et al. 
1996; Zufferey, Nagy et al. 1997).  
As mentioned above, the fact that lentiviruses are able to transduce non-dividing or 
slowly dividing cells has widened the range of hosts where this technology could be 
applied. Of particular interest for gene therapy are the HSC. In accordance with this, 
many publications described the efficient transduction of human HSC (CD34+) 
capable of reconstitute non-obese diabetic/severe combined immunodeficient mice 
(NOD/SCID) (Uchida, Sutton et al. 1998; Salmon, Kindler et al. 2000; Woods, 
Fahlman et al. 2000; Trono 2001; Woods, Mikkola et al. 2001). Today, lentiviral 
vectors are seen as potent tool for genetic engineering and their use in basic research 
as well as possible clinical applications has generated great expectations. 
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1.6. Aim of the study 
 
Therapeutic agents currently used for the treatment of neurodegenerative diseases as 
Multiple Sclerosis and cerebral ischemia are not curative and many problems can be 
found when attempting to deliver any therapeutic molecule specifically to the lesioned 
tissue in the CNS. Using adult bone marrow derived lineage negative hematopoietic 
stem/progenitor cells two different animal models for neurodegeneration and their 
progress after a cell and molecular therapy approach were examined.  
Depending on the mouse model used the following specific goals were chosen: 
 
1) The first biological question of this work was whether hematopoietic 
stem/progenitor cells derived from bone marrow and genetically modified to express 
NT-3 would ameliorate the disease course of the animal model for multiple sclerosis.  
In that respect, a cell population enriched in progenitor and stem cells was isolated 
from murine bone marrow and genetically modified to express NT-3. The animal 
model for multiple sclerosis was induced by immunization with the myelin antigen 
MOG35-55. Intravenously cell injection was performed and clinical outcome was 
analyzed. 
 
2) As there is little data on the kinetics and tissue protection of bone marrow 
hematopoietic stem/progenitor cells entering the ischemic area after intravenous 
administration, the second biological question was to assess the effects of 
hematopoietic stem and progenitor cell injection post-infarction in an animal model of 
transient cerebral ischemia. 
For that purpose a transient ischemia animal model was induced by middle cerebral 
artery occlusion. Bone marrow hematopoietic stem/progenitor cells were injected 
intravenously 24 hours after ischemia. Brain hemispheres and spleens collected from 
injected animals were analyzed for cell migration, pathologic phenotype and 
expression profiles of growth factors and cytokines. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Buffers and solutions 
 
 (10X) 0.125M Phosphate-Buffered Saline (PBS), pH 7.3 
Components Concentration Company 
NaH2PO4.H2O 
Na2HPO4.7H2O 
NaCl 
ddH2O 
0.007M 
0.034M 
0.6M 
up to1 liter 
Roth, Germany 
Roth, Germany 
Roth, Germany 
Roth, Germany 
 
 4% paraformaldehyde (PFA), pH 7.3 
Components Amount Company 
PFA 
NaOH 
PBS(10X) 
ddH2O 
20g 
30ml 
50ml 
up to 1 liter 
Sigma, Germany 
Roth, Germany 
 
Roth, Germany 
 
 Lysis buffer for erythrocytes 
Components Concentration Company 
NH4Cl 
KHCO3 
EDTA 
ddH2O 
0.156M 
0.01M 
5x10-6M 
 
Roth, Germany 
Roth, Germany 
Roth, Germany 
Roth, Germany 
 
 (10X) TBE Buffer  
Components Concentration Company 
Tris-Base 
Boric Acid 
EDTA 
ddH2O 
1.78M 
1.78M 
0.04M 
 to 2 liters 
Roth, Germany 
Sigma, Germany 
Roth, Germany 
Roth, Germany 
 
 (6X) Loading buffer 
Components Concentration Company 
EDTA 
Sucrose 
Bromphenol Blue 
Xylene Cyanole 
Ficol-400 
0,5M 
60% 
0,04% 
0,04% 
2% 
Roth, Germany 
Fluke Biochemika, Germany 
Sigma, Germany 
Sigma, Germany 
Bio-Rad, Germany 
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• 1% Agarose gel  
Components Amount Company 
Agarose 
Etidium Bromide or 
Gel Star (when gel extraction) 
 
TBE (1X) 
0.5g 
1.25ul 
4ul 
 
50ml 
SeaKem,Cambrex, USA 
Roth, Germany 
BioWhittaker Molecular 
Applications, USA 
 
 
• PCR reaction mix (50 ul sample) 
Components Amount Company 
dNTP mix (10mM) 
Taq polymerase(100U/20ul) 
Forward primer (10pmol/ul) 
Reverse primer (10pmol/ul) 
Buffer (10X) 
dd H2O 
1ul 
0.5ul 
3ul 
3ul 
5ul 
37.5ul 
Amersham Bioscience, USA 
Roche, Germany 
MWG, Germany 
MWG, Germany 
Roche, Germany 
Roth, Germany 
 
• Reverse transcription (RT) mix (20 ul sample) 
Components Amount Company 
Total RNA 
Hexanucleotide Mix (10X) 
dNTP mix (10 mM) 
DTT mix (0.1M) 
5XRT 1st Strand Buffer  
RT enzyme (200U/ml) 
dd H2O 
5ug 
1uL 
1uL 
2uL 
4uL 
1uL 
up to 20ul 
 
Roche, Germany 
Amersham Bioscience, USA 
Invitrogen, Germany 
Invitrogen, Germany 
Invitrogen, Germany 
Roth, Germany 
 
• Real time RT-PCR (25 ul sample) 
Components Amount Company 
SYBR Green Master Mix(2x) 
cDNA 
forward and reverse primer 
pair mix (10 pmol/ul) 
ddH2O 
12.5ul 
1ul 
 
1ul 
10.5ul 
Applied Biosystems, UK 
 
 
MWG, Germany 
Roth, Gemany 
 
• Digestion reaction mix (20 ul sample) 
Components concentration Company 
Enzyme 1 (10U/ul) 
Enzyme 2 (10U/ul) 
Buffer (10X) 
insert/plasmid 
ddH2O 
0.5ul 
0.5ul 
2ul 
up to1ug 
up to 20ul 
Roche, Germany 
Roche, Germany 
Roche, Germany 
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• Ligation reaction mix (10ul sample) 
Components Concentration Company 
T4 Ligase (1U/ul) 
Ligation Buffer (10X) 
DNA 
ddH2O  
1ul 
1ul 
8ul 
10ul 
Roche, Germany 
Roche, Germany 
 
Roth, Germany 
 
3.1.2. Cell culture media and reagents  
 
• 293FT cell line (based on human embryonic kidney cell line HEK): 
 
Components Concentration Company 
DMEM 
Fetal Calf Serum 
1% L-Glutamate 
1% Penisilin/Streptomycin 
1% Glucose 
Genetycin (when 
expanding) 
 
10% 
1% 
1% 
1% 
1% 
Gibco, Germany 
PAN, Germany 
Gibco, Germany 
Gibco, Germany 
Sigma, Germany 
Gibco, Germany 
 
• Lineage negative cells  
 
Components Concentration Company 
Stem Span SFM 
 
rhInterleukin-6  
rmStem Cell Factor  
rmThrombopoietin  
 
 
 
20ng/ml 
100ng/ml 
20ng/mL 
Stem Cell Technologies,Vancouver, 
Canada 
R&D systems, Germany 
R&D systems, Germany 
Sigma, Germany 
 
 
• Other cell culture reagents 
 
Opti-MEM (reduced serum medium) 
Trypsin-EDTA(1X)  
Poly-L-Lysine  
Gibco, Germany 
Gibco, Germany 
Sigma, Germany
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3.1.3. Antibodies 
 
• Cell isolation and flow cytometry monoclonal primary antibodies 
 
Epitope Specificity Source Company 
B220/CD45R B lymphocytes Rat BD Pharmingen, USA 
CD4 T lymphocytes  Rat BD Pharmingen, USA 
CD8 T lymphocytes Rat BD Pharmingen, USA 
Gr-1 Granulocytes Rat BD Pharmingen, USA 
Mac-1(CD11b) Macrophages Rat BD Pharmingen, USA 
TER-119 Erythroid cells Rat BD Pharmingen, USA 
CD45 (LCA) Pan-hematopoietic 
(except erythrocytes) 
Rat BD Pharmingen, USA 
c-Kit HSC Rat BD Pharmingen, USA 
Sca1 HSC Rat BD Pharmingen, USA 
CXCR4  HSC, B cells Rat BD Pharmingen, USA 
CXCR3 lymphocytes Rat R&D Systems, De 
β1-integrin 
(CD29) 
lymphocytes Rat BD Pharmingen, USA 
α4-integrin 
(CD49d) 
lymphocytes Rat BD Pharmingen, USA 
Isotype IgG - Rat BD Pharmingen, USA 
 
 
 
• Additional inmunohistochemistry monoclonal primary antibody 
 
 
 
• Secondary antibodies and other staining reagents 
 
Fluorophore Specificity Source Company 
- 
 
FITC 
Cy3 
FITC 
Cy3 
- 
 
- 
Rat 
 
Rat 
Rat 
- 
- 
microglia/ 
macrophages 
double stranded DNA
Goat (magnetic bead 
conjugated) 
Goat  
Goat 
Avidin-conjugated 
Avidin-conjugated 
Biotinylated 
IsolectinB4 
DAPI 
Dynal, USA 
 
Dianova, Germany 
Sigma, Germany 
Sigma, Germany 
Sigma, Germany 
 
Sigma, Germany 
Sigma, Germany 
  
 
Epitope Specificity Source Company 
Myelin Basic 
Protein 
 
Myelin sheath rat Chemicon, Germany 
Materials and Methods  
 
 41
 
3.1.4. Primer sequences (all pimers were purchased from MWG, Germany) 
 
• Table I. Real time RT-PCR primers 
 
Target Accession number 
Oligo 
nucleotide Sequence 
forward 5’-ACTGGCAAAAGGATGGTGAC-3’ IFN-γ NM_008337 reverse 5’-TGAGCTCATTGAATGCTTGG-3’ 
forward 5’-ACAACAAAAAAGCCTCGTGCTG-3’ IL-1β NM_008361 reverse 5’-CCATTGAGGTGGAGAGCTTTCA-3’ 
forward 5’-CCGTCAGCCGATTTGCTATCT-3’ TNF-α NM_013693 reverse 5’ACGGCAGAGAGGAGGTTGACTT-3’ 
forward 5’-GCTGAGCGTGTGTGACAGTA-3’ BDNF BC034862 reverse 5’-TTGGATACCGGGACTTTCTC-3’ 
forward 5’-GCTGCTGGCTTCTAAGTGTG-3’ bFGF NM_008006 reverse 5’-TACTGCCCAGTTCGTTTCAG-3’ 
forward 5’-CCTCGAAGAGAGAGGAATCG-3’ GDNF NM_010275 reverse 5’-ATAGCCCAAACCCAAGTCAG-3’ 
forward 5’-TCTATACTGGCCGCAGTGAG-3’ NGF NM_013609 reverse 5’-GCTTCAGGGACAGAGTCTCC-3’ 
forward 5’-AAATAGTCACACGGATGCCA-3’ NT-3 NM_008742 reverse 5’-GGCAAACTCCTTTGATCCAT-3’ 
forward 5’-AGGACCTGGGTTGGAAGTGG-3’ TGF-β NM_011577 reverse 5’-AGTTGGCATGGTAGCCCTTG-3’ 
forward 5’-CGAAGTGGTGAAGTTCATGG-3’ VEGF BC061468 reverse 5’-AAGATGTCCACCAGGGTCTC-3’ 
forward 5’-ACAACTTTGGCATTGTGGAA-3’ GAPDH BC083149 reverse 5’-GATGCAGGGATGATGTTCTG-3’ 
forward 5’-CTCATGCAGCATAGGAGGCTT-3’ CCR1 NM_009912 reverse 5’-ACATGGCATCACCAAAAATCCA-3’ 
forward 5’-ATCCACGGCATACTATCAACATC-3’ CCR2 NM_009915 reverse 5’-CAAGGCTCACCATCATCGTAG-3’ 
forward 5’-TTTTCAAGGGTCAGTTCCGAC-3’ CCR5 NM_009917 reverse 5’-GGAAGACCATCATGTTACCCAC-3’ 
forward 5’-GGAGTGGGGTCTGGAGACTAT-3’ CXCR4 NM_009911 reverse 5’-TTGCCGACTATGCCAGTCAAG-3’ 
forward 5’-TACCTTGAGGTTAGTGAACGTCA-3’ CXCR3 NM_009910 reverse 5’-CGCTCTCGTTTTCCCCATAATC-3’ 
forward 5’-GAGTATGACGATTCTGCTGAGG-3’ CX3CR1 NM_009910 reverse 5’-CAGACCGAACGTGAAGACGAG-3’ 
 
• Cloning primers 
 
Target Oligo Sequence 
Forward 5’-CCATCGATAATTCTACCGGGTAGGGGGAGG-3’ PGK 
prom Reverse 5’-CGCGGATCCGGAGATGAAGGAAGAGGAGAAAC-3’ 
Forward 5’-GGGGATCCAATGTCCATCTTGTTTTATGTGATA-3’ NT-3 
Reverse 5’-GGCTCGAGTCATGTTCTTCCAATTTTTCTCGAC-3’ 
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• RT-PCR primers 
Target Oligo Sequence 
Forward 5’-CAATTCCCTCATCATCAAGCTGA-3’ NT-3 
Reverse 5’-CTCGGTGACTCTTATGTTCTGC-3’     
Forward 5’-ATCCATTGGAGGGCAAGTCT-3’          18s 
Reverse 5’-CCGCGGTCCTATTCCATTAT-3’           
 
3.1.5. Consumables 
 
6 and 24-well culture plates  
15ml tubes   
50ml tubes  
5ml, 10ml, 25ml pipets  
Chamber slides  
Cryovials  
75cm2 and 175 cm2 culture flasks  
5ml polystyrene round-bottom tubes  
3cm,10cm culture dishes  
Bacteria culture 10ml tube 
500ul, 1000 uL plastic tube 
PCR tubes  
10ul, 100ul and 1000ul tips  
96 well- optical reaction plate  
5ml, 10ml syringes  
Needles  
Stopcock for infusion 
Glass slices for cryosectioning  
Bottle top filters (0.25um pore) 
Filters (0.45um and 0.2um pore) 
Cellstar, VWR International, Germany 
Cellstar, VWR International, Germany 
Sarstedt, Germany 
Sarstedt, Germany 
Nunc GmbH, Germany 
VWR International, Germany 
Sarstedt, Germany 
BD Falcon, USA 
Sarstedt, Germnay 
Sarstedt, Germany 
Eppendorf, Germnay 
Biozym Diagnostik, Germany 
Starlab, Germany 
Microamp, Applied Biosystems, Germany 
Braun, Omnifix, Labomedic, Germany 
100Sterican, Braun, Germany 
Discofix, Braun, Germany 
Menzel-Glacer, Germany 
Millipore, Germany 
Filtropur, Sarstedt, Germany
 
Materials and Methods  
 
 43
 
3.1.6. Equipment and software 
Centrifuges 
 
 
 
 
Cryostat 
 
Flow cytometer 
 
Electrophoresis gel chambers  
 
Power supply 
 
Heating block 
 
Incubators 
 
Laminar-Air-flow workbench 
 
Microscopes 
 
 
 
pH-meter 
 
Photometer 
 
Real time thermocycler   
 
 
Thermocycler  
 
Transiluminator  
 
Vortex 
 
Scale 
 
-80°C Freezer  
 
Magnetic stirrer 
 
 
 
 
 
Ultracentrifuge, Sorvall DiscoveryTM 90SE, Hitachi,
Germany 
Megafuge, 1.OR. Heraeus, Germany 
Biofuge Fresco, Heraeus, Germany  
 
Micron HM560,  Microm Int., Germany 
 
FACSCalibur, Becton Dickinson Bioscience, Germany 
 
Blomed Analitik GmbH, Germany 
 
Amersham Bioscience, Germany 
 
Stuart Scientific, Germany 
 
Heracell240,  Heraeus, Germany 
 
Herasafe, Heraeus, Germany 
 
 Axiovert40CFL, Zeizz, Germany 
 Axiovert200M, Zeizz, Germnay 
Fluoroview1000 Confocal micr., Olympus, Germany 
 
 Hanna Instruments, Germany 
 
Biophotometer, Eppendorf, Germany 
 
ABI Prism 5700 Sequence Detection System,
Applied Biosystems, UK 
 
T3, Biometra, Germany 
 
Dark Reader, Clare Chemical Research, Germany 
 
2X2, VelpScientifica, Germany 
 
Sartorious, Germany 
 
Herafreeze, Heraeus, Germany 
 
Velp Scientific, Germany 
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3.1.7. Kits and additional reagents 
 
• DNA and RNA purification kits 
 
Kit name Purpose Company 
Endofree Plasmid Maxiprep 
QIAprep Plasmid Miniprep 
Min iElute Gel extraction 
Mini Elute Clean up 
RNeasy Mini 
RNeasy Mini for lipid tissue 
Plasmid extraction (up to 500ug) 
Plasmid extraction (up to 20ug) 
DNA (70bp-4kb) extraction from agarose gels 
DNA (70bp-4kb) purification  from reactions 
Total RNA (up to 100ug) purification 
Total RNA (up to 100ug) purification from 
lipid tissue 
All from 
Qiagen, 
Germany 
 
• Additional reagents 
 
MOG35-55 (MEVGWYRSPFSRVVHLYRNGK)  
Pertussis toxin  
Mycobacterium Tuberculosis H37Ra  
Incomplete Freund’s adjuvant 
Lipofectamine2000 reagent   
Ampicilin  
LB agar and LB media 
DMSO  
Glycerol  
Tissue tek O.C.T. compound  
β-Mercaptoethanol  
Ethanol 
Propidium Iodide 
Charité, Berlin
List Biological Laboratories, 
USA 
Difco, USA 
Difco, USA
Invitrogen, Germany 
Sigma, Germany 
Fluke Biochemika, Germany 
Sigma, Germany 
Sigma, Germany 
Sakura, NL 
Sigma, Germany 
Roth, Germany 
Sigma, Germany
 
Software Openlab4.0.1, Improvision, Germany
CorelDRAW. Graphics Suite 11, Germany
EndNote v8,Thomson ISI ResearchSoft, USA 
Microsoft Office XP, Microsoft USA, USA
Olympus FluoView1.4. Olympus, Germany
SDS 2.2.2, Applied Biosystems, USA
Cellquest Pro, BD Biosciences, USA
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2.2. Animals 
Green fluorescent protein (GFP) expressing transgenic mice (in these mice, the 
expression of GFP is under the chicken ß-actin promoter and the cytomegalovirus 
(CMV) enhancer ensuring the expression of this fluorescent molecule in all tissues with 
the exception of erythrocytes and hair) were obtained from JAX laboratories and bred 
in heterozygosis in the animal facility. Normal C57Bl/6 mice were obtained from 
Charles River (Sulzfeld, Germany). Female animals of 6-8 weeks of age were used for 
Lin--HSC isolation and EAE induction. Adult male C57Bl/6N mice weighting 22-27g 
were used for all stroke experiments. 
2.3. Isolation of lineage negative cells (Lin--HSC) from adult mice BM 
To isolate BM cells, mice were sacrificed, skin and muscle were removed from their 
hind limbs, ends of the bones were cut off and BM from femora and tibiae was flushed 
out using a 27 gauge needle and 5 ml syringe, and collected in 5 ml of cold phosphate-
buffered saline (PBS, 1X). Erythrocytes were lysed using 1ml/mouse of hypotonic 
solution for 30 sec. Immediately, PBS was added preventing further lysis of white 
blood cells and the suspension was centrifuged (5 min. 2000 rpm 4°C). After a second 
washing step, total BM (TBM) cells were collected.  
For removing cells positive for blood lineage markers, TBM was incubated for 1 hr in a 
rotor at 4°C, with a suspension of six types of rat monoclonal antibodies against mice 
lineage markers as listed bellow: 
 Surface Marker   Cell lineage 
B220/CD45R B lymphocytes
CD4 T lymphocytes
CD8 T lymphocytes
Gr-1 Granulocytes 
Mac-1 Macrophages 
TER-119 Erythrocytes 
(All 1:200, BD Pharmingen, USA) 
After a washing step, a population devoid of lineage markers was isolated by 
incubating the cell and antibodies suspension with sheep anti-rat IgG secondary 
antibody coupled with immune-magnetic bead (1:10, Dynabeads M-450, Dynal, USA) 
with rotation during 45 min at 4°C. The bead-bounded cells were depleted from the 
total population by placing the tube in a magnet (also from Dynal) for 10 min. before 
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collection of the non-magnetic fraction (Lin--HSC). Cells were counted before and after 
selection in a Neubauer chamber of 0.0025 mm2.  
After a washing step, Lin--HSC were either use for FACS or real time RT-PCR 
analysis, incubated with viral particles for genetic modification and/or injected into 
animals for in-vivo migration study or therapeutic approach. 
 
2.4. Total Bone Marrow and Lin--HSC cell analysis 
 
2.4.1. Flow cytometry  
TBM cells or Lin--HSC were incubated with either biotin-conjugated anti-CD45, anti-
cKit (1:200, BD Biosciences) or anti-CD11b, anti-TER119, anti-Gr-1, anti-B220, anti-
CD8, anti-CD4, anti-Sca1, anti-CD29, anti-CD49d, anti-CXCR4 or anti-CXCR3 rat 
anti-mouse monoclonal antibodies for 30 min at 4°C (same concentration).  
After a washing step, cells were incubated with FITC-conjugated streptavidin in the 
same concentration (BD Biosciences) or FITC-conjugated goat anti-rat IgG secondary 
antibody (Dianova, Hamburg, Germany). Isotype matched antibodies (BD 
Biosciences) were used as negative control. Analysis was done with a FACSCalibur™ 
flow cytometer (BD Biosciences). Live gating was preformed using propidium iodide 
(PI, 1ug/ml, Sigma). PI can be excluded from living cells, therefore only cells 
negative for fluorescence coming from PI are consider for analysis. 
2.4.2. RNA extraction, reverse transcription and real-time PCR quantification 
RNA was isolated from TBM or Lin--HSC using RNeasy minikit (Qiagen). The 
principle of the procedure of this kit is the selective binding of RNA to a silica 
membrane while the rest of the cell components are washed away. 
As starting material, 2 million cells from each population were disrupted by addition 
of buffer containing ß-mercaptoethanol 1% (Sigma) and homogenized to reduce 
viscosity of lysates. Afterwards, ethanol 70% was added to provide proper binding 
conditions to the silica-gel membrane of the columns provided by the kit. Finally, 
RNA molecules longer than 200 nucleotides are eluted in 30ul of water. 
To obtain DNA copy (cDNA), reverse transcription (RT) was performed using 
approximately 3ug of RNA isolated as described above. SuperScript III reverse 
transcriptase enzyme (Invitrogen) and hexamer random primers (Roche) were used for 
this reaction during 1 hour at 50°C. This enzyme is able to synthesize a 
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complementary DNA strand (and the supplementary copy) from single chain RNA. 
Thereafter, the product of this synthesis was utilized as template for the relative 
quantification step. As control of possible genomic DNA contamination, samples 
without the reverse transcriptase enzyme were prepared. 
Relative expression levels of the following cytokines and factors were determined: 
TNF-α, IFN-γ, IL-1ß, Transforming Growth Factor (TGF)-ß, BDNF, basic Fibroblast 
Growth Factor (bFGF), Glial-cell-line-derived Neurotrophic factor (GDNF), NGF, 
NT-3 and Vascular Endothelial Growth Factor (VEGF). List of specific primers for 
each transcript is detailed in Table I of Materials, primer sequences section.  
Real time quantitative Polymerase Chain Reaction (PCR) was performed using an 
ABI Prism 5700 Sequence Detection System machine (Applied Biosystems), which 
detects fluorescent signal coming from a reporter during the PCR amplification 
reaction. SYBR green (emits signal only when intercalates in double stranded DNA) 
was the fluorescent dye of choice which is included in the PCR master mix from 
Applied Systems together with the polymerase enzyme (AmpliTaq Gold). The 
amplification protocol for the GeneAmp 5700 Sequence Detection System Software 
(v.2.2) was performed. Cycles were as follows: initial denaturalization at 95°C for 10 
min, denature at 95°C for 15 sec., annealing and amplification at 60°C for 1 min. 
repeated 40 times. Non-template control and negative samples from reverse 
transcription were included. Glyseraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used as endogenous gene expression control. After the reaction, the melting curve 
program was perfomed to assess the presence of specific products. A peak in the 
negative first derivative of the fluorescence versus temperature graph indicated a 
unique specific product in the amplification reaction.  
To analyze the values obtained from the real time reaction the comparative Ct 
(treshold cycle) method was used. Normal brain tissue was used as calibrator sample 
(gene expression value=1). 
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2.5. Lentivirus based vector system 
 
2.5.1. Cloning into Lentiviral vectors 
Lentiviral vectors of third generation (pLenti6/V5 D-TOPO, Invitrogen) were used for 
genetic modification of cells. The CMV original promoter was replaced for the 
phosphoglycerate-kinase (PGK). In hematopoietic derived cells, the PGK promoter 
allows the ubiquitous and stable in time expression of the desire gene.  
The PGK promoter was amplified from the murine stem cell virus plasmid (pMSCV; 
Clontech) using extended primers for ClaI and BamHI restriction sites (please, refer to 
Materials, cloning primers). 
Downstream the promoter, enhanced GFP (eGFP) reporter gene was inserted into the 
TOPO cloning sites or for therapeutic approach GFP was cut out using BamHI and 
XhoI (Roche). The mouse NT-3 gene (NM_008742) of 777 base pairs previously 
amplified using extended primers was inserted. Accordingly, gene expression was 
confirmed with transfection of the packaging cell line by fluorescence imaging or RT-
PCR (primers detailed in Materials, RT-PCR primers list). 
2.5.2. Viral particle production  
The 293FT (purchased from Invitrogen and expanded in the laboratory) packaging 
cell line was kept in Dulbecco's Modified Eagle's Medium (DMEM; Gibco) with 1% 
penicillin/streptomycin and glucose (Sigma) at 37°C in 10% CO2.  
In order to produce viral particles, 5 million 293FT cells were seeded in 10 cm dishes 
precoated with poly-L-Lysine (Sigma). After removing the culture medium and 
washing once with PBS, 5 ml of Opti-MEM medium (Gibco) without antibiotics were 
added. Cells were transfected using the gene-containing vector (either GFP or NT-3) 
together with three packaging helper plasmids and Lipofectamine 2000 reagent 
(Invitrogen).  
The principle of this procedure is the entrance of the DNA to the cells after forming 
lipidic complexes form with the Lipofectamine2000 reagent. Medium was replaced 
for fresh DMEM 10 hrs post-transfection.  
Viral supernatant (10 ml) was collected at 48-72 hrs post-transfection. To increase 
viral titres, particles were concentrated by ultracentrifugation (25000 rpm for 1 hr. 
30min at 4°C) using a Sorvall DiscoveryTM 90SE ultracentrifuge. Supernatant was 
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removed, and pellet resuspended by slightly shivering the tubes overnight at 4°C in 
500ul of medium. Viral particles were immediately used for Lin--HSC or control cell 
line transduction. 
2.5.3. Transduction of Lin--HSC 
To genetically manipulate cells to express a fluorescent molecule or alternatively a 
neurotrophic factor the lentiviral technology (Invitrogen) was preferred.  
For transduction Lin--HSC, cells were normally seeded at a density of 1x106cells/ml 
in 24-well dish and incubated with 108 Transducing Units (TU)/mL of lentiviral 
particles. First, cells were centrifuge for 90 min. at 2000 rpm and 30°C (spin down 
protocol) in Stem Span serum free medium (StemCell Technologies Inc., Canada) in 
the presence of rhIL-6 (20ng/ml), rmSCF (100 ng/ml) and rmTPO (20ng/mL) (all 
from R&D systems). After centrifugation step, cells were placed in 37°C and 5% CO2 
incubator overnight.  
When attempting to improve transduction efficiency, the proteasome inhibitor MG-
132 (Calbiochem, Germany) was added together with the cytokines at a concentration 
2uM. 
Alternatively, the glycoprotein VSV that pseudotypes the lentivirus capside (coded in 
the plpVSV helper plasmid) was replaced by the SCF, which is the ligand for the cKit 
receptor. SCF was cloned into the plpVSV packaging vector (G-VSV was replaced by 
the SCF of 821bp using EcoRI restriction sites). Both vectors (plpVSV and plpSCF) 
were used to co-transfect 293FT cells when preparing viral particles and transduction 
followed as before. 
The day after Lin--HSC transduction, medium containing viral particles was removed 
and fresh medium was added. FACS analysis of eGFP expression was performed 
between days 3 to 5 post-transduction. Alternatively, injection into EAE animals for 
therapy approach, took place 24 hrs after cell transduction. To this aim, cells were 
washed and re-suspended in 300uL of PBS. 
2.6. Induction of Experimental Autoimmune Encephalomyelitis 
 
2.6.1. Myelin Oligodendrocyte Glycoprotein (MOG) emulsion  
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; Charité, Berlin) was 
emulsified with 1 mg of Mycobacterium Tuberculosis H37Ra (Difco, Detroit, MI) in 
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incomplete Freund’s Adjuvant (Difco). Emulsion was left overnight at 4ºC the day 
before mice immunization. 
2.6.2. Immunization of animals with MOG35-55 peptide 
For immunization protocol, adult 6-8 weeks old female C57Bl/6 mice were 
anesthetized and injected subcutaneously in both inguinal lymph node regions with 
200 ug of MOG35-55 emulsion. 
PTX (200 ng, List Biological Laboratories, Campell, CA) was injected on day 0 
(intravenously) and 2 (intraperitoneally). Weight and clinical score of animals was 
checked daily for at least 30 days thereafter unless moribund.  
Scoring of clinical symptoms was as follows: 
0- Healthy 
1- Complete limp tail 
2- Weakness of hind limbs 
3- Paralysis of hind limbs 
4- Weakness of fore limbs 
5- Fore and hind limbs paralysis or moribund 
Animals with a clinical score less than 1 by day 14 post-immunization were not used 
for the study. For migration and therapeutic studies, mice were intravenously injected 
with GFP positive or NT-3 transduced Lin--HSC 5 days after the onset of disease.  
2.7. Detection of GFP+ Lin--HSC in injected animals. 
Animals were transcardially perfused with 20ml of PBS followed by 20ml of cold 4% 
PFA. Spinal cords and spleens were collected and left overnight in fresh fixative. The 
day after, tissues were cryoprotected in 2% DMSO (Sigma), 10% glycerol (Sigma) 
containing PBS for one extra day. Tissues were embedded in Tissue-Tek O.C.T. 
compound (Sakura, NL), rapidly frozen on dry ice and stored in -80°C till 
cryosectioning. Slicing was performed in a Micron HM560 cryostat at -20°C. 
Thickness of slices was between 10 to 20um. 
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For immunohistochemistry, cryo-sections were re-fixed in PFA 4%, washed and 
incubated with monoclonal first antibody diluted in 0.1% Bovine Serum Albumin 
(BSA) and 0.01% Triton-X (1:200, BD Pharmingen) overnight at 4°C. After 2 
washing steps, secondary fluorophore conjugated anti-rat IgG was added (1:200, 
Dianova) for 2 hrs at room temperature. Counterstaining of nuclei was performed 
using DAPI (1:5000, Sigma).  
Sections were analyzed both, by normal flourescence (Zeiss) and confocal microscopy 
(Olympus) 
 
2.8. Induction of focal cerebral ischemia and Lin--HSC injection 
(In collaboration with the Department of Neurology, University Hospital Göttingen) 
 
Transient focal cerebral ischemia (45 minutes) was induced by occlusion of the middle 
cerebral artery (MCA) using the intraluminal filament technique (Kilic, Bahr et al. 
2001). Briefly, animals were anaesthetized with initially 4% isofluran and then 
maintaining 1%-1.5% isofluran in 68% N2O and 30% O2 using a facial mask. Rectal 
temperature was maintained between 36.5-37°C employing a feedback-controlled 
heating system. For assessment of cerebral blood flow (CBF), laser-Doppler flow 
(LDF) was recorded during all experiments using a flexible 0.5mm fiber-optic probe 
(Perimed, Sweden) attached to the intact skull overlying the core region of the MCA 
territory (2mm posterior, 6mm lateral from Bregma). Following a midline neck incision 
the left common and external carotid artery were isolated and ligated. After placing a 
microvascular clip (Aesculap, Germany) on the internal carotid artery, an 8-0 silicon 
resin (Xantopren; Deuker, Germany) coated nylon monofilament (Ethilon, thread 
diameter 180-200µm; Ethicon, Germany) was introduced through an incision into the 
distal part of the common carotid artery and, after removing the clip, advanced 9mm 
distal from the carotid bifurcation for MCA occlusion. Only mice that showed a 
constant decrease in CBF to at least 30% of baseline values were used for our study. 
After 45 minutes of ischemia the filament was removed to allow reperfusion of the 
MCA. LDF recordings were continued for 15 minutes to monitor appropriate 
reperfusion (>80% of initial CBF). 
Twenty-four hours after reperfusion mice were randomly selected to receive either Lin-
-HSC or PBS. Firstly, animals were (re-)anaesthetized as described above, 
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subsequently, the left femoral vein was isolated and a 30 gauge needle attached to a 
polyethylene micro catheter (PE10) was introduced. Animals were injected with 5 
million Lin--HSC (dissolved in 200µl of PBS) over 20 minutes. Control animals 
received PBS (200µl) only. 
2.9. Brain and spleen tissues real-time RT-PCR analysis  
For analysis in brains of cytokine and neurotrophic factor expression following stem 
cell treatment in cerebral ischemia, Lin--HSC-treated animals and PBS-control mice 
were sacrificed 72 hours after intravenously treatment. Brains were carefully removed, 
and right and left (infarcted) hemispheres were separated. RNA was isolated by the 
RNeasy Mini Kit for Lipid Tissue (Qiagen). Reverse transcription was performed as 
described earlier. Levels of the same neurotrophic factors and cytokines mentioned 
above were determined for the ischemic and healthy hemispheres separately. 
To assess peripheral immune activation, spleens were removed 24 hrs post cell or PBS 
administration. Same procedure as before for RNA isolation RT and real time PCR 
was followed. Expression of the following transcripts was analyzed: TNF-α, IFN-γ, 
IL-1β, Chemokine Receptor (CCR)-1, CCR2, CCR-5, CXCR1, CXCR3, CX3CR1. 
 
 
 
2.10. Appendix to Materials and Methods 
 
RNA Isolation 
Isolation of RNA was performed using the RNeasy Mini Kit (Qiagen, Germany). The 
protocol used is summarized as follows: 
• Take tubes with tissue (e.g. 20-30mg in PBS). 
• Add 700µl lysis buffer (inc. 1:100 β-mercaptoethanol), use 350µl if less than 20mg 
of tissue or less than 5x106 cells (lysis buffer lasts approx. 1 month). 
• Homogenize with small syringe (use large first if a lot of tissue). Centrifuge (3min, 
max). 
• Mix 600µl of supernatant with 600µl EtOH (70% in dd H2O). 
• Add 700µl into column and centrifuge (15s, 10000rpm), throw away waste, add rest 
of mixture and repeat. 
• Add 350µl wash buffer RW1 and centrifuge (15s, 1000rpm), throw away waste. 
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• Mix 10µl DNase1 with 70µl RDD buffer, add to filter and leave for 15min. 
• Add 350µl wash buffer RW1 and centrifuge (15s, 10000rpm), throw away waste. 
• Add 500µl wash buffer RPE (+EtOH) and centrifuge (15s, 10000rpm), remove 
waste, repeat and centrifuge (2min, max). Remove waste and centrifuge again to dry 
(1min, max). 
• Place column in tube, add 35µl RNase free H2O (onto filter), leave for 3 min, 
centrifuge (1min, 10000), throw away column. RNA is collected in 1.5ml tube. 
• Measure concentration (µg/ml) and RNA/protein absorption (260/280) using 
photometer (Eppendorf), and dilute with ddH2O accordingly to start with about 3 µg 
of sample RNA. 
 
Polymerase Chain Reaction (PCR) 
Polymerase chain reaction was performed for the amplification of specific cDNAs in 
order to obtain gene products for insertion into viral expression constructs, as well as 
for analysis of sequences inserted into such constructs following mini-prep plasmid 
preparation. 
In cases where correct sequences were required a polymerase with high proofreading 
ability was used, Vent Polymerase (New England Bio Labs), whereas in cases of 
analysis a standard Taq Polymerase was used (Roche). A master mix was prepared 
containing all required reagents (see Materials, buffers and solutions) and aliquoted to 
PCR tubes according to the following protocol: 
• Add 47.5µl master mix to each tube. 
• Add 2µl of appropriate cDNA (nothing to negative control). 
• Place tubes into PCR machine and choose required program (use heated lid!). 
 
Example of PCR program: 
Initial Denaturation Step: 94oC 3min 
Cycle Step 1 – Denaturation: 94 oC 1min 
Cycle Step 2 – Annealing 55-60 oC 1min (dependent upon primers used) 
Cycle Step 3 - Elongation 74 oC 1min (3min for Vent Polymerase) 
Repeat cycle steps accordingly between 15 to 35 times. 
Final Elongation Step: 74 oC 3min. 
PCR products were either stored at 4oC or run on a 1% agarose gel for analysis or 
extraction of the product. 
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Agarose Gel Analysis and Extraction 
In order to observe PCR products they were run on a 1% agarose gel. For analysis, 
ethidium bromide was added to the gel to allow visualization under a U.V. lamp. 
Where extraction of the product was required, “Gelstar” (BioWhittaker Molecular 
Applications) was used instead of ethidium bromide to allow visualization without the 
use of an U.V. lamp and thus preventing the possibility of mutation. After setting the 
gel in the chamber (see Materials, buffers and solutions) proceed as follows: 
• Add a mixture of 3µl loading dye and 6µl sample to each lane, using a ladder in one 
lane to evaluate product size. 
• Connect to power supply and set to 120V, 110A for 30min. 
• Visualize DNA under a U.V. lamp. 
• For extraction, visualize using a transiluminator (Dark Reader), cut out required 
fragment and extract DNA. 
 
Extraction of DNA from agarose was performed using the QIAquick Gel Extraction 
Kit 
(Qiagen) as follows: 
• Excise DNA fragment and weigh. 
• Add 3xVol buffer QG to 1xVol gel (max 400mg, normally use 450µl). 
• Leave at 50oC for 10 min (vortex every 3min). 
• Add 1xVol isopropanol (normally use 150µl), invert several times, place in column, 
centrifuge 1min, discard flow through. (Qiagen column collects fragments within 
range of 70bp-10Kb). 
• Add 500µl QG buffer, centrifuge 1min, discard flowthrough. 
• Add 750µl buffer PE, centrifuge 1min, discard flowthrough, repeat centrifugation. 
• Place column in clean tube, add 10µl EB buffer/H2O, leave 1min, centrifuge 1min. 
 
Real-time RT-PCR 
Pipet reaction mix accordingly prepared (see Materials, buffers and solutions) into 
wells. Add 1ul of cDNA. Use a “non-template control” (NTC) well only with master 
mix. When pipetting, avoid bubbles. Cover the plate, with the plastic lid. 
Program on ABI Prism SDS 7000 (Standard Protocol)  
Cover T°= 105°C !! 
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Initial denature: 95°C, 10min 
Denature: 95°C, 15sec 
Annealing: 60°C, 60sec 
Amplification for 40 cycles 
Final elongation: 72°C, 10min 
To asses if a specific product was obtained, perform dissociation curve analysis. 
(95°C, 60°C, 95°C ramp rate 2%). 
(Alternatively, the PCR outcome can be examined by 3% agarose gel using 5 µl from 
each reaction)  
Analyze the real-time PCR result with the SDS 7000 software. Check to see if there is 
any bimodal dissociation curve or abnormal amplification plot. 
 
Blunt-end Formation and Dephosphorylation 
In cases where “sticky-end” ligation could not be performed blunt-end ligation was 
used. 
This procedure required dephosphorylation of the end terminals of the digested 
plasmid in order to prevent self-religation. 
• Perform restriction digestion in a 20µl mixture as mentioned above. 
• Without any manipulation on the reaction mix (e.g. cleaning or changing buffer) add 
0.5µl of 10 mM dNTP. 
• In order to fill in “sticky-ends” add 1-5 U Klenow Enzyme (Roche) and incubate at 
30oC for 15 min. 
• Block the reaction by heating at 75oC for 10 min (not necessary if continuing with 
dephosphorylation). 
Proceed with dephosphorylation of the plasmid: 
• Extract the necessary DNA fragment into 15µl H2O by gel extraction. 
• Add 2µl 10x Buffer and 3U Shrimp Alkaline Phosphatase (Roche), bring to total 
volume of 20µl. 
• Incubate for 60 min at 37oC degrees. Inactivate by heating to 65oC for15 min. 
• Purify dephosphorylated plasmid by gel extraction and ligate to blunt-end-insert. 
 
Ligation 
Ligation of insert into plasmid was performed using T4 DNA Ligase (Roche). 
Ligation reactions were normally carried out at 15°C for at least 3 hours. The reaction 
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mix used was as listed below. Normally a ratio of 1:3 or 1:15 was used for 
plasmid:insert DNA in a volume of 8µl. 
 
Transformation 
Chemically competent bacteria (TOP10 Chemically Competent E.Coli, Invitrogen) 
were transformed with ligated insert-plasmid DNA and expanded according to the 
following protocol: 
• Defrost chemically competent cells on ice (500µl per tube). 
• Aliquot 100µl of cells per transformation and leave on ice for 30min. 
• Dilute ligation mix 1:1 and add 0.6µl to 100µl of competent bacteria. 
• Heat-shock cells at 42oC in water bath for 1min. 
• Return cells to ice for 2min. 
• Add 1ml LB medium and incubate in for 45min at 37°C (rotatory shaker, >200rpm). 
• Centrifuge for 3min at 7000rpm and remove excess medium. 
• Plate onto appropriate selective LB plates and incubate at 37°C overnight. 
• Pick colonies and grow in selective LB medium for 10hr at 37°C in shaker. 
• Isolate plasmid DNA using mini-prep kit (Qiagen). 
• Verify ligation by restriction digest and PCR. 
• Prepare high concentrate stock of positive samples using maxi-prep kit (Qiagen). 
 
Transfection 
Transfection of cell lines was performed to produce lentiviral particles as well as to 
confirm the expression of genes cloned into plasmids. Lentiviral particles were 
produced by co-transfection of the lentiviral plasmid along with plasmids expressing 
accessory lentiviral genes into a packaging cell line using a lipofectamine-based 
technique as follows: 
• Plate 5x106 293FT cells in a poly-L-lysine coated 10cm dish one day before 
transfection to obtain a culture of 80-90% confluence. 
• On the day of transfection add antibiotic-free medium to the cells (10ml). 
• Prepare DNA-lipofectamine complexes: 
9ug packaging mix + 3ug vector in 1.5ml Opti-MEM medium (Gibco). 
36ul Lipofectamine 2000 (Invitrogen) in 1.5ml Opti-MEM 
leave for 5min at room temperature. 
mix gently and leave for 20min at room temperature 
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• Add transfection mix to cells dropwise, mix gently and leave for 6 hours. 
• Add medium containing antibiotics and 2% serum to the transfected cells. 
• Remove supernatant 36-72hrs post-transfection and pellet the debris. 
As the lentivirus is VSV-G pseudotyped, the supernatant may be stored overnight at 
4oC, frozen at -80oC or concentrated by ultracentrifugation (25,000rpm, 4oC, 90min). 
 
Transduction 
A number of different transduction protocols can be used depending upon the target 
cell. 
• Supernatant (cell lines) 
Cells at a confluency of 30-50% were treated with lentiviral supernatant and kept at 
37oC overnight. Fresh medium was added to the cells on the following day. 
Expression normally reached its peak 48hr post-transduction. 
• Supernatant Spin Infection (cell lines) 
Cells at a confluence of 30-50% in 6-well dishes were treated with lentiviral 
supernatant, centrifuged (2500rpm, 30oC, 90min) and kept at 37oC overnight. 
Fresh medium was added to the cells on the following day. Expression normally 
reached its peak 48hr post-transduction and was generally higher than that observed 
following regular supernatant treatment. 
 
• Viral Concentrate (primary HSC and cell lines) 
Viral particles concentrated by ultracentrifugation were resuspended overnight at 4oC 
in 500µl serum free medium (e.g. Stem Span). The resuspended viral concentrate was 
added to the target cells and kept at 37oC overnight. Fresh medium was added to the 
cells on the following day. Expression normally reached its peak 48hr post-
transduction. 
 
• Concentrate Spin Infection (primary HSC and cell lines) 
Viral particles concentrated by ultracentrifugation were resuspended overnight at 4oC 
in 500µl serum free medium. The resuspended viral concentrate was added to the 
target cells, centrifuged (spin infection: 2500rpm, 30oC, 90min) and kept at 37oC 
overnight. Fresh medium was added to the cells on the following day. Expression 
normally reached its peak 48hr post-transduction and was generally higher than that 
observed following other transduction procedures. 
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Kill Curve 
The pLenti6/V5 plasmid expresses the antibiotic blasticidin to allow selection of 
transduced cells in culture. The following protocol was used to determine the 
minimum concentration of blasticidin required to kill non-transduced cells: 
• Plate cells in a 6-well plate at a confluency of 25%. 
• Add blasticidin at various concentrations, e.g. 0, 2, 4, 6, 8, 10 ug/ml. 
• Change medium every 3-4 days. 
• Observe the percentage of surviving cells. 
• Determine the lowest concentration that kills all cells within 10 days of treatment. 
 
Viral Titre Determination 
Titration of the viral titre may be performed using FACS analysis to quantify the 
number of transduced cells in order to estimate the concentration applied to primary 
hematopoietic cultures. Cells (can be from a cell line like HeLa) are transduced as 
follows: 
• Plate 5x104 cells per well in a 6 well culture dish. 
• Prepare 10-fold serial dilutions of viral stock (10-6, 10-5, 10-4, 10-3, 10-2, 0). 
• Add to cells in total volume of 2ml medium containing 6ug/ml polybrene. 
• Leave overnight at 37oC. 
• Add fresh medium and leave overnight at 37oC. 
Transduced cells are allowed to culture for 4 days following transduction and then 
analyzed by FACS (normally best done using a GFP reporter gene construct). Only 
dilutions yielding to 1-20% GFP-positive cells should be considered for titer 
calculations. Below 1%, the FACS may not be accurate enough to give a reliable 
determination of the number of GFP+ cells. Above 20%, the chance for each GFP+ 
target cell to be transduced twice significantly increases, resulting in underestimation 
of the number of transducing particles. The following formula is used to calculate the 
viral titre:  
Titer (Hela-transducing units / ml) = (5x104 Hela cells) x (% GFP-positive cells/100) 
                                                                     volume of supernatant (ml) 
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3. Results 
3.1. Lin--HSC isolation from adult mouse bone marrow 
There are three main stem cell populations described to be present in mouse BM, the 
endothelial, the mesenchymal and the HSC, this last consisting of a lesser quantity in 
the total population (Wang and Spangrude 2003). In an ideal situation, when highly 
pure HSC need to be obtained, a very accurate sorting method and a large number of 
mice are required as source of BM, as this stem cell group represents less than 0.007% 
of the TBM. In addition, many difficulties are found when keeping these pure cells in 
culture for a long time without losing their stem properties. 
To obtain a sufficient cell number for a cell therapy approach, an enriched 
hematopoietic precursor and stem cell population, here termed Lin--HSC, was selected 
for this work. These cells were immuno-magnetically negatively sorted. The protocol 
consisted of a step of depletion of blood committed cells expressing surface lineage 
markers. For this purpose, TBM cells were incubated with a mixture of primary abs 
against six different lineage epitopes (anti-TER-119 for erythrocytes, anti-Mac-1 for 
macrophages, anti-Gr-1 for granulocytes, anti-CD8 and anti-CD4 for T lymphocytes 
and anti-B220 for B lymphocytes) and after with magnetic bead conjugated secondary 
abs.  
After a final incubation of the cell suspension in a magnetic column, the non-adherent 
fraction was used for following experiments. 
 
The non-magnetic fraction obtained after the negative isolation step described above 
represented an average of 21±5.6 % of the initial TBM population (12 independent 
isolation times, figure 3.1). This average was reproducible in further isolations. 
Results 
 
 60
TBM Lin--HSC cKit+
0
10
20
30
40
50
60
To
ta
l c
el
l n
um
be
r 
(x
10
6 )
 
Figure 3.1. Isolation of lineage negative fraction from 
murine total bone marrow. Bars show the averaged cell 
number of absolute values per mouse. TBM: total bone 
marrow cells when freshly isolated from bone. Lin--HSC: 
cells after negative selection and number of cKit+ cells in 
TBM. Data is shown as the mean +/- S.D. (n=12 isolation 
times).  
3.2. Flow cytometry characterization of Lin--HSC 
To assess the reliability of the depletion procedure and describe which molecules are 
present on the surface of the cells obtained after negative selection, flow cytometry 
analysis was performed. TBM or selected cells were marked for the six different 
epitopes used for their isolation, followed by a secondary ab conjugated to a 
fluorescent molecule.  
The Lin--HSC population obtained after negative selection was devoid of molecular 
markers for blood differentiated in contrast with TBM cells (figure 3.3A). Therefore, 
the depletion method selected in this work shown to be a trustworthy protocol to 
obtain a non-committed enriched cell population.  
 
Further characterization by flow cytometry was performed with respect to surface 
markers and receptors present in the cells. As they are described markers for stem 
cells, levels of Sca-1 and c-Kit were assessed. Double positive cells never exceeded 
1.2 % of the Lin--HSC. A representative dot plot for double staining is shown in figure 
3.2. 
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Figure 3.2. Representative flow cytometry dot plot 
showing percentage of double cKit and Sca1 positive 
cells in the Lin--HSC population. 
 
Lin--HSC were found to be positive for CD45 (up to 58%) and the level of ckit 
expression shown was 29% (figure 3.3B). Chemokine-chemokine receptor is a system 
involved in recruitment of cells to sites of inflammation. The expression levels of two 
of the main chemokine receptors involved in this migration process was checked. No 
detectable levels of expression of CXCR3 and CXCR4 chemokine receptors in the 
purified cells were found (figure 3.3B). Once cells are recruited to sites of 
inflammation firm adhesion between migrating cells and endothelium is mediated by 
molecules of the Integrin superfamily. These molecules are expressed in the cell 
surface as heterodimers. Cells were checked for expression of two subunits of these 
Integrins. The subunit beta-1 was found not to be expressed and only 1% of Lin--HSC 
showed alpha-4 subunit signal expression (figure 3.3B). In Table 3.I, flow cytometry 
values are summarized for all markers mentioned above. 
Therefore, upon isolation, the population of choice for this work was devoid of 
lineage committed markers while expressing others belonging to a stem/progenitor 
phenotype. At the same time, they were not having detectable levels of chemokine 
receptors and of integrins analyzed once freshly obtained. Up to 85% of committed 
cells were eliminated with this procedure. 
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Figure 3.3. Representative flow cytometry analysis histograms of freshly isolated 
total bone marrow and selected Lin--HSC. A) After isolation from BM and 
immuno-magnetic negative selection, Lin--HSC showed undetectable levels of 
blood lineage committed cells.  
B) Lin--HSC were positive for CD45 and cKit, while low levels of chemokine 
receptors and adhesion molecules were detected. Isotype controls are shown in grey 
(closed histograms). In the upper right corner, representative values of the markers 
are shown.  
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Marker 
Total 
Bone 
Marrow 
Lin--HSC
CD11b 55.4±3.8 1.7±1.6 
TER119 6.0±1. 2 1.5±1.4 
Gr-1 34.4±4.6 3.0±2.9 
B220 3.4±2.3 0.1±0.1 
CD8 1.7±0.8 0.5±0.4 
CD4 2.0±1.0 0.5 ±0.1 
Ckit 25.9±9.5 18.7±12.2
CD45 84.2±0.1 50.8± 8.7 
CXCR3 6.9±2.1 <0.1 
CXCR4 44.7±4.7 2.0±1.1 
Beta-1 20.84±0.1 <0.1 
Alpha-4 72.0±10.0 0.91±0.01
 
Table 3.I. Percentage of surface markers of 
Total Bone Marrow and lineage negative 
cells. Flow cytometry data from 3 
independent experiments are shown. Values 
are presented as the mean ± SD. 
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3.3. Real time RT-PCR analysis of total bone marrow and Lin--HSC 
As an additional method of characterization of the population used for this work, gene 
transcription levels were compared between Lin--HSC and TBM cells and analyzed in 
relation to their respective counterparts in normal brain tissue for a number of 
inflammatory cytokines and growth factors. 
 
After isolation, TBM cells, Lin--HSC and brain tissue were lysed, RNA was extracted 
and reverse transcription performed. Thereafter, the cDNA obtained from each sample 
was used as a template for real time RT-PCR. For analysis, the comparative Ct 
method was used. Expression levels were normalized to brain gene transcripts levels 
(calibrator expression value = 1). Expression of the following cytokines and growth 
factors were determined: TNF-α, IFN-γ, IL-1ß, BDNF, bFGF, GDNF, NGF, NT3, 
TGF-ß, VEGF. 
 
After three independent experiments, no relevant levels of growth factors and trophic 
factors BDNF, bFGF, GDNF, NGF, NT-3, TGF-ß, VEGF were observed in the Lin--
HSC (figure 3.4A).  
At the same time, Lin--HSC showed significantly decreased gene transcript levels of 
the pro-inflammatory cytokine TNF-α. Although not significant, also lower levels of 
IFN-γ, and IL-1ß were seen in the Lin-HSC when compared to TBM cells (figure 
3.4B).  
 
Therefore, cells obtained after the immune depletion step are not able per se to 
generate considerable levels of relevant growth factors for neuronal support and 
survival. In addition, levels of cytokines related to inflammation were reduced in 
comparison with TBM cells, which are already mature blood cells.  
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Figure 3.4. Relative gene transcription levels of cytokines and growth 
factors of Lin--HSC and total bone marrow cells. The population lacking 
lineage markers was found not to express considerable levels of growth 
factors (A) and reduced levels of pro-inflammatory cytokines when 
compared to total bone marrow (B). 
Mean ± S.E.M are shown for the values normalized to expression 
level in brain (value=1). Data were analyzed using the Mann-
Whitney Test (*, p<0.05; n=3). 
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3.4. Induction of Experimental Autoimmune Encephalomyelitis  
A mouse model for MS was established. For this purpose, C57Bl/6 female mice were 
injected with MOG35-55 peptide and developed a progressive relapsing disease with a 
late mild remission. Disease susceptibility observed in this work is detailed in the 
following table: 
 
 
 
 
Table 3.II. EAE disease susceptibility of C57Bl/6 mice strain 
used for this work. Incidence (%), mean time of disease onset 
(days) and mean maximum clinical score ± S.E.M are shown 
for 9 independent immunization times.   
 
As specified above, the incidence of the disease was between 60% and 70%. Onset of 
clinical symptoms was observed generally at days 10 to12 after immunization. 
Maximal clinical score was between 3 and 3.5 and was observed at days 4 to 5 after 
onset of the symptoms (this was the time point chosen for cell injection in the 
migration and therapeutic approaches). Only mice that showed onset (score more than 
1) of clinical symptoms before day 14 were considered for the following experiments. 
 
 A graph showing typical outcome data from four mice in which EAE was induced 
independently is depicted in figure 3.5. A decrease in the weight can be observed 
immediately after immunization with a second point of weight loss together with the 
first clinical manifestations. Minimal weight values coincide with worsening of the 
clinical symptoms at 4 to 5 days after onset of disease. 
Histopathological analysis was performed in order to complement the observations of 
clinical symptoms of EAE. As expected, large areas of infiltrates which stained 
positive for IsolectinB4 were observed specially in the peri-vascular regions in spinal 
cord (figure 3.6A). Staining for CD45 showed also regions of immune cell infiltration 
(figure 3.6B). MBP immunohistochemistry revealed areas of myelin loss 20 days after 
EAE induction (figure 3.6B).  
 
 
Mouse 
Strain Incidence Disease onset 
Maximal 
clinical score 
C57Bl/6 64±15% 11±1 days  
after immunization
3±0.5 
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Figure 3.5. Representative diagram of mean values (±S.E.M) of 
relative (to initial) body weight change and clinical score of 4 
independent immunized mice, during course of EAE. 
Mice usually lost weight during first 2 days and 4 to 5 days after the 
first symptoms. This time point coincided with worsening of the 
clinical score. The arrow represents the cell injection time point chosen 
for the migration and therapeutic approaches. 
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Figure 3.6. Staining of spinal cords from EAE mice at day 20 after disease 
induction (worsening of clinical symptoms phase). A and B) Fluorescence 
microscope images. Areas of high number of infiltrates are revealed by the 
nuclear staining DAPI and stained positive for the macrophage/microglia 
marker IsolectinB4. C and D) Confocal images. C) Immunostaining for 
CD45 revealed also areas of infiltration. D) MBP staining allows 
visualization of damaged myelin regions.  
All scale bars: 50 um. 
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3.5. Lin--HSC effect and migration after injection into EAE mice  
It has already been reported that cells derived from BM can migrate to different 
tissues including CNS after injection. In contrast to local cell injection protocols, a 
systemic application was performed while clinical outcome and migratory behaviour 
of the cells was studied. 
Lin--HSC were isolated from GFP transgenic mice (GFP+ Lin--HSC). In total, 5 
million cells were injected into the tail vein of EAE non-transgenic C57Bl/6 mice. 
EAE mice were injected with an equal volume of PBS as control. For cell 
administration, a time point of 5 days after the first clinical symptoms was chosen. 
Clinical score and weight were followed daily. No changes in disease outcome were 
observed when comparing GFP+ Lin--HSC to control PBS injected (figure 3.7).  
0 5 10 15 20 25 30
0
1
2
3
4 PBS
GFP+Lin-HSC
Days post-immunization
C
lin
ic
al
 s
co
re
 
Figure 3.7. Average ± S.E.M of EAE course of animals that were 
injected with 5 million GFP+Lin--HSC or PBS 5 days after first 
symptoms. Mice that received Lin--HSC did not differ from the 
PBS injected controls in respect to their clinical score. Arrow: 
injection time point.  
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To assess the migratory behaviour, in particular to sites of the CNS where 
inflammation takes place, histological analysis was performed. As an additional 
control for migration experiments an equal amount of GFP+ Lin--HSC were 
administered to healthy aged matched mice. Animals were sacrificed 5 days after cell 
administration (21 days after EAE induction) and intra-cardiac perfusion with a 
fixative was performed. After collecting spinal cords and spleens, tissues were frozen 
and slices were prepared in a cryostat.  
As previously observed under our experimental conditions, GFP+ cells were found in 
spleen and spinal cords of EAE mice. Quantification of 5 representative spinal cord 
areas bearing GFP+ cells showed 25.4±14.5 cells/mm2 (figure 3.8). Healthy controls 
showed cell migration only towards spleen and no GFP+ cells in the spinal cord could 
be found. 
More detailed morphological analysis of the migrated cells by confocal microscopy 
was performed. Morphology strongly suggests the GFP+ cells found in spinal cord to 
present a microglia-like phenotype (figure 3.9). 
 
 
A B C
 
Figure 3.8. Representative confocal images showing GFP+ cells detected within the spinal 
cord tissue of EAE mice. Cells were intravenously injected 5 days after the onset of 
symptoms. Mice were analyzed 5 days after cell application. Overlay of green fluorescence 
and phase contrast is shown. Scale bars A) 50um, B) and C) 100um.  
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Figure 3.9. A-C) Confocal images and D) 3D reconstruction 
depicting different morphologies observed in GFP+ Lin--HSC 
found in spinal cord 5 days after administration into EAE mice. 
Scale bars A-D): 10 um. 
 
3.6. Lin--HSC present undetectable CD45 levels in the EAE spinal 
cord 
To start assessing the phenotype of the Lin--HSC present once they have migrated to 
the CNS in EAE mice, immunohistochemistry for CD45 was performed on cryoslices. 
As mentioned before, CD45 surface molecule expression levels in the freshly isolated 
Lin--HSC assessed by flow cytometry was around 58% (figure 3.3 and Table 3.I). 
Analyzed GFP+ cells found in spinal cord didn’t show co-visualization of GFP and 
CD45 markers (figure 3.10).  
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Therefore, data may indicate that the phenotype of these injected cells could change to 
a microglial-like cell type after contact with new cues, in particular within the CNS 
environment.  
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Figure 3.10. Immunohistochemistry analysis of GFP+Lin--HSC injected into 
EAE mice and found in spinal cord 5 days after injection. A-B) No 
colocalization of CD45 and GFP+ signals was observed in spinal cord 
engrafted cells. C) colocalization of CD45 and GFP found in spleen. Scale 
bars: 50 um 
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3.7. Lin--HSC present a microglia/macrophage-like phenotype in the 
EAE spinal cord 
Further histochemistry analysis was performed to assess which phenotype the Lin--
HSC may present once in the CNS environment. IsolectinB4 labeling revealed that a 
high number of cells within the spinal cord of EAE mice were positive for this 
macrophage/microglia marker (figure 3.11). Quantification of GFP+ cells showed that 
approximately 53% of these cells (n=200) were positive for the microglia/macrophage 
marker. Therefore a microglia/macrophage surface molecule profile was confirmed 
for the Lin--HSC when analyzed in EAE spinal cord 5 days after administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. A-D) Confocal images showing 
covisualization of GFP+ cells detected in spinal cord of 
EAE mice and found to be positive for Isolectin B4 
staining (Cy3). Scale bars: 10um 
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3.8. Lentiviral vectors and Lin--HSC transduction 
To genetically manipulate the cell population chosen in this work, two vectors 
containing either a fluorescent marker (eGFP) or NT-3 neurotrophic factor were 
created (please see scheme on figure 3.12). 
 
Figure 3.12. Schematic representation of the constructs used to genetically modify the 
Lin--HSC. In a Lentiviral vector backbone, the PGK promoter was inserted. Downstream, 
the eGFP gene was inserted between the TOPO cloning sites. For the therapy approach, 
the GFP cassette was removed by the use of BamHI and XhoI restriction enzymes and the 
gene for the mouse NT-3 was inserted by ligation after being amplified with extended 
primers for the same enzymes 
 
In these vectors the gene of interest is under the control of the PGK promoter. 
Although intricacies for modifying murine lineage negative cells using lentivirus 
derived vectors under our experimental conditions were faced before, the system was 
tested for assessing the percentage of lineage negative cells expressing the reporter 
gene after transduction.  
First, the vector expressing eGFP was used to transfect the packaging cell line 293FT 
in order to prepare viral particles. Upon transfection almost 100% of the packaging 
cell line was positive for eGFP (figure 3.13). 
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Figure 3.13. Upon transfection using a PGK promoter driven eGFP 
expression lentiviral construct, the packaging cell line 293FT were 100% 
positive for eGFP expressing cells Scale bar: 20 um. 
 
 
After selection, Lin--HSC were transduced with the eGFP containing viral particles 
produced as described above in the 293FT cells. When using non-ultracentrifuged 
freshly collected from the packaging cells line viral supernatant (106 TU/ml), no eGFP 
expression was observed in the Lin--HSC, when checked after a period of 5 days. 
Transduced 293FT cell line as procedure control showed 70% of eGFP+ cells.  
Thereafter, a protocol to augment viral titer (108-109 TU/ml) was chosen. Viral fresh 
supernatants were ultracentrifuged and the pellet containing viral particles were re-
suspended in a low volume of media (500ul). Efficiency of lineage negative cell 
transduction using these concentrated viral particles was analyzed by flow cytometry. 
Three days after incubation with the concentrated viral particles up to 16% of cells 
were positive for eGFP (figure 3.14A). Further cell transduction has been in the range 
of this value. 
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Alternative strategies were considered during this work to improve transduction 
efficiency and specificity. The proteasome inhibitor MG-132 was applied during viral 
incubation with the cells. This pharmacological proteasome inhibition has been 
reported to increase transduction of human HSC up to 90% (Santoni de Sio, Cascio et 
al. 2006).  
A dose of 2 uM of MG-132 was used. After three independent transduction 
procedures no significant differences in the percentage of eGFP positive cells was 
found (figure 3.14B). Higher amounts (4 and 8 uM) of the MG-132 led to massive cell 
death (assessed by PI staining and flow cytometry analysis), while lower 
concentrations (0.5 and 1uM) showed even lower levels of GFP+ cells than the non-
MG132 treated control (data not shown). 
 
Alternatively, production of a hybrid pseudotyped virus which could be specific for 
transducing the cKit positive cells was challenged. To that aim, SCF, the ligand for 
cKit receptor (expressed in the undifferentiated cell population) was cloned into the 
plpVSV packaging vector. Membrane SCF expression was up to 90% after 
transfection of the 293FT, analyzed by flow cytometry (data not shown). Virus 
supernatant was ultra-centrifuged and assessed for the transduction of Lin--HSC.  
In this case of transduction, a ratio of percentage of eGFP positive cells of the relative 
amount of cKit positive cells was compared between plpVSV and plpVSV+plpSCF 
pseudotypes. After 3 independent transduction procedures, no significant differences 
were found between the original G-VSV and the hybrid pseudotyped virus (table 
3.III). 
 
 
Capside pseudotype Mean ± SD 
 %eGFP/cKit+ cells (n=3)
plpVSV 18.15±9.8 
plpVSV+plpSCF 27.8±21 
 
Table 3.III. Averaged percentages of eGFP obtained 
for the cKit+ fraction of the Lin--HSC. No significant 
differences in the eGFP expression levels were found 
between plpVSV or plpVSV+plpSCF pseudotyped 
virus particles.    
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Figure 3.14. Lentiviral gene transfer system was used to genetically 
manipulate the Lin--HSC. A) Representative flow cytometry histogram and 
dot plot showing transduction level achieved assessed by eGFP expression 
level. Cells were lentivirally transduced using viral titers up to 108 TU/ml 
and analyzed 3 days thereafter. B) A pharmacological inhibitor of the 
proteasome pathway was used in order to improve transduction levels. A 
slight but not significant improvement of eGFP levels was observed with a 
concentration of 2uM (n=3). 
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3.8.1. Neurotrophin-3 expression 
To confirm correct expression of the NT-3 trophic factor selected for the therapeutic 
approach at the mRNA level, RT-PCR was performed in the 293FT cell line 2 days 
after transduction. A band for the amplified portion of the NT-3 gene was observed in 
the agarose gel analysis. No amplification product was detected in the control eGFP 
transduced cells (figure 3.15).  
 
 
 
 
 
 
 
 
 
Figure 3.15. Agarose gel analysis of RT-PCR products for NT-3 
transcript and 18s after cell transduction. M: size marker (100 base 
pairs leader). Gene transcripts derived from cells transduced with eGFP 
or NT-3 were either reverse transcribed (+) or non-transcribed (-) and 
amplified by PCR. DNA derived from the PGK-NT3 vector was used 
as a positive control. 
 
3.9. Injection of NT-3 transduced Lin--HSC into EAE mice 
It is clear that several factors are involved in the pathophysiology of MS and its 
animal model EAE. A successful treatment of such complex diseases would imply a 
multi-component approach capable of compensating/controlling the 
neurodegeneration taking place. Nevertheless, it has been shown that a reduced 
availability of neurotrophic factors may contribute to the neurodegenerative state in 
these diseases. 
                           GFP                       NT-3         PGK-NT-3
     M            +             -            +            -      vector     M                                     
NT-3 341bp
18s 243 bp
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A molecular therapy approach was used to asses if the use of cells able to migrate into 
spinal cord lesion areas (and secondary lymph organs) and eventually provide nervous 
and immune systems with an over-expression of one of these neurotrophic factors, 
NT-3 would compensate the symptoms observed during EAE disease progression. 
At first, Lin--HSC were isolated and immediately transduced with lentiviral particles 
containing the mouse NT-3 gene under the PGK promoter. As control, Lin--HCS cells 
were incubated in parallel with PGK-eGFP containing vector. 
 
After transduction, a total of 3-5 million cells expressing either NT-3 or eGFP, were 
intravenously injected into EAE mice 5 days after disease onset (days 15-16 after 
MOG33-55 immunization). Clinical score and weight of the animals from 4 independent 
induction procedures were controlled daily. None of them presented any modification 
of clinical symptoms when compared with eGFP transduced cells as injection controls 
(figure 3.16). 
 
Spinal cords were taken from animals treated with NT-3 expressing cells, alternatively 
eGFP expressing cell injected were used as controls. After RNA isolation and reverse 
transcription, levels of NT-3 were assessed by real-time RT-PCR. On average, spinal 
cords from mice injected with NT-3 bearing cells, expressed 3±1 fold more NT-3 
when compared to spinal cords from eGFP-cell injected mice (data not shown). 
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Figure 3.16. Averaged clinical scores observed for EAE mice following injection of Lin--HSC 
over-expressing NT-3. In total, 3 to 5 million cells were lentivirally transduced and 
intravenously injected at day 5 after first clinical manifestations (arrow). Same amount of eGFP 
transduced cells or PBS were used as control. NT-3 expressing cells were not able to modify 
the clinical course of the disease (n=4). 
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3.10. Injection of Lin--HSC into a mouse model of transient cerebral 
ischemia  
To this extent, an interesting cell population coming from BM, the Lin--HSC were not 
capable of modifying the course of disease in the animal model for MS. Nevertheless, 
the cell isolation protocol was reliable and it seemed worthwhile to challenge another 
model of neurodegeneration for the therapeutic approach of applying this 
undifferentiated cell population.  
In collaboration with the Neurology Department at University Hospital Göttingen, 
transient focal cerebral ischemia in adult C57Bl/6 mice was induced using the middle 
cerebral artery occlusion (MCAO) model. A decrease of the brain blood flow to at 
least 30% of baseline values was controlled by laser Doppler flow (LDF) 
measurements. After 45 min., reperfusion was allowed and values of blood flow 
recovered to more than 70% of the initial values. At 24 hours after reperfusion, 
animals received an intravenous injection of 5 million Lin-- HSC previously isolated 
from GFP transgenic mice as described before. At 24, 48 and 72 hours after cell 
administration tissue analysis was performed. 
 
Injected GFP+ Lin--HSC increased in number over time in the infarcted tissue. The 
cell number per ischemic hemisphere changed significantly from 146±43 at 48 hours 
to 798±335 at 72 hours. At 48 hours after cell injection, GFP+ cells were located in 
the parenchyma (65%) but also in the meninges (13%) and perivascular space (22%). 
At 72 hours post cell administration, GFP+ cells were mainly (90%) located in the 
brain parenchyma within the ischemic hemisphere (Schwarting et al. Submitted). 
GFP+ cells found within the brain parenchyma 72 hrs after injection displayed a 
microglial-like phenotype and were positive for Isolectin B4 and CD11b-specific abs 
(figure 3.17). 
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Figure 3.17. Histochemical analysis of GFP+ Lin--HSC within ischemic hemispheres at 72 
hrs post-injection. The microglia/macrophage marker IsolectinB4(IB4-Cy3) was found to 
colocalize with GFP+ signal, suggesting a microglial fate of the injected cells.. Nuclei was 
counterstained using DAPI. Scale bars: 20 um. 
 
In addition, infarct size determination was performed on cresyl stained cryo-sections 
at 72 hours after Lin--HSC- or PBS-treatment. Lin--HSC-treated animals (n=6, 
18.3±3.9 mm3) showed significantly smaller infarcts when compared to PBS-treated 
controls (n=7, 41.3±8.8 mm3) (Schwarting et al. Submitted). Whereas the cerebral 
infarcts measured about 50% (49.3±4.9%) of the normal hemisphere in PBS-treated 
controls, it comprised less than 30% (26.8±4.6) of the contralateral hemisphere in Lin-
-HSC-treated mice (Schwarting et al. Submitted). 
The number of Isolectin B4 and CD3 cell within ischemic lesions was assessed. Lin--
HSC treatment decreased significantly the number of Isolectin B4 positive cells (from 
2887± 194/mm2 in PBS-injected mice to 2355±275/mm2) and the same was observed 
when CD3 cells were quantified (from 1226± 124/mm2 in PBS injected to 995± 
194/mm2). The application of Lin--HSC clearly reduced immune infiltration and 
activation in ischemic hemispheres (Schwarting et al. Submitted). 
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3.11. Real-time RT-PCR for cytokines and neurotrophic factors in 
brains derived from Lin--HSC or PBS-treated animals. 
 
Some reports suggested that stem/progenitor cells could provide trophic support to 
damaged neuronal tissue. To answer the question of whether exist a difference in the 
expression levels of a number of cytokines and growth factors between the ischemic 
hemispheres of Lin--HSC and PBS injected mice, real time RT-PCR analysis was 
performed. 
RNA was extracted from 9 ischemic brain hemispheres of each group, (PBS or cell-
injected mice) as well as from normal mice. As described before, RT was performed 
and relative quantitative real-time RT-PCR analysis was done. Data was compared to 
normal brain for the expression of the factors: TNF-α, IFN-γ, TGF-β, BDNF, NT-3, 
NGF, IL-1ß, bFGF, GDNF or VEGF (figure 3.18). 
 
No significant differences in the growth factors BDNF, bFGF, GDNF, NGF, NT3, 
TGFβ and VEGF were observed between Lin--HSC and PBS treated animals. A slight 
but no significant difference in the gene transcript levels of the pro-inflammatory 
cytokines TNF-α and IFN-γ was observed.  
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Figure 3.18.  Real time RT-PCR analysis of cytokines and growth factors of the 
ischemic hemispheres from Lin--HSC injected and PBS mice at 72 hours post-cell 
administration. No significant differences were found between these two groups. Data 
was normalized to normal brain tissue (value 1) and is presented as the mean ± S.E.M 
(n=9 independent experiments). 
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3.12. Real-time RT-PCR for cytokines and chemokine receptors in 
spleens derived from Lin--HSC or PBS-treated animals. 
A clear reduction in brain inflammation and together with reduced infract size was 
found after 72 of Lin--HSC administration in comparison with PBS treated controls. 
At the same time, no local trophic support in the brain environment was detected by a 
number cytokines and trophic factors, it is tempting to speculate about an immune 
modulation taking place in the periphery of the treated animals 
In order to study the grade of immune activation in peripheral immune tissues, spleens 
derived from normal and ischemic animals (PBS or Lin--HSC injected) were analyzed 
at 24 hrs post cell injection. 
Real time RT-PCR data showed a tendency to down-regulation of inflammatory 
cytokines together with chemokine receptors when comparing Lin--HSC injected 
animals with PBS controls (figure 3.19). 
 
 Figure 3.19. Spleen real time PCR for several inflammatory cytokines and 
chemokine receptors. After 24 hrs of cell administration a tendency of a 
reduced inflammatory profile and activation was observed. Data from 3 
independent experiments are shown (Mean ± S.E.M.). 
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4. Discussion 
In this work a BM population comprising of an enriched stem and progenitor cells was 
isolated from adult mice BM. Cell surface molecules and relevant gene transcript 
levels were analyzed confirming the lack of blood committed cell markers and their 
poor expression of inflammatory and trophic factor molecules when freshly isolated. 
Moreover, cell migration behavior and potential therapeutic effects were assessed 
after administering these cells to two different animal models of neurodegeneration. 
While cells migrated specifically to lesion sites in the spinal cord in the animal model 
for MS, they were not able to interfere with the course of the disease as a cellular 
therapy themselves or as a combined cellular and gene therapy approach applying 
genetically modified cells over-expressing the neuronal growth factor NT-3. On the 
other hand, cells migrated into damaged hemispheres in an animal model of cerebral 
ischemia. Moreover, animals that were administered with this enriched 
stem/progenitor cell population showed a reduction of infarcted tissue and 
inflammation when compared to controls.  
4.1. Isolation and characterization of adult mouse Lin--HSC  
When selecting a population suitable for a prospective cell therapy approach, there are 
several features to be taken into consideration. Adult stem cells are a promising cell 
type to take advantage of. They could be relatively easy obtained from the patient, 
expanded and genetically modified in culture. In addition, ethical issues related with 
the clinical use of human embryonic derived stem cells could be avoided. 
From the many stem cells currently studied for prospective therapeutic use, the adult 
HSC are one of the best characterized, and they are very promising respect to the 
range of pathologies for their possible application. This cell type is already used in 
clinical applications and they are highly effective as for instance, as blood lineage 
repopulation treatment when High-Dose Chemotherapy is required (e.g. in myeloma 
cases, HSC are obtained from peripheral blood and re-transplanted into the patient). In 
addition, the use of the HSC as therapy beyond blood-related diseases, as nervous 
tissue repair, has started to be explored.  
 
If a high number of extremely pure HSC from the BM is needed for a certain study, 
then many animals would be required as a cell source and an accurate method to 
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isolate them would had been necessary, as they represent an extremely small 
percentage of the whole BM population (<0.007%). Nevertheless, the use of a 
complete un-selected BM population could introduce artifacts and side effects derived 
from an uncontrolled immune action of the committed blood cells. In order to obtain a 
suitable number of cells for a therapy approach, a depletion step of adult BM lineage 
committed cells was followed for this work. A stem/progenitor cell enriched BM 
fraction, (lineage negative cells, Lin--HSC) was obtained through a reproducible 
negative-selection protocol. The majority of cells showing a mature phenotype were 
efficiently eliminated. 
 
Since being first described, several markers to clearly define the phenotype of HSC 
(mouse and human) have been proposed. Although it is now accepted that they may 
display heterogeneity in their properties (cell cycle status, self renewal, pluripotency) 
even when isolated as a phenotypically homogeneous population, the described profile 
of surface markers that currently defines them is: Thy-1.1(low), Lineage(-/lo), Sca-1+ 
and the exclusion of rhodamine and Hoechst dyes (Uchida, Aguila et al. 1994; Uchida, 
Jerabek et al. 1996). In this work detected c-Kit tyrosine kinase receptor levels in the 
Lin--HSC were acceptable (around 30%). In addition, Lin--HSC showed a high 
percentage of the CD45 (a membrane tyrosine phosphatase) surface expression, which 
is used to distinguish cell of the hematopoietic lineage from the endothelial lineage.  
As expected, a relatively high expression level of chemokine receptors (CXCR4 and 
CXCR3) and integrin subunits (α4 and β1) was observed for TBM preparation as it 
contains mature immune cells ready to enter into blood circulation. In parallel, 
negligible surface expression levels of these chemokines and integrins were found in 
the Lin--HSC population. This poor migration receptor and adhesion molecule 
detection under the experimental conditions of this work could be explained in part, 
by the absence of stimulating factors in the isolation protocol. Supporting this concept, 
it was shown that human CD34+ cells (mainly HSC), when treated with human 
recombinant SCF, up-regulated homing related molecules, increasing their ex vivo 
trans-migratory and in vivo homing potential (Glimm, Tang et al. 2002; Zheng, 
Watanabe et al. 2003). It is worth to mention that publications claim the relevance of 
the CXCR4 receptor in keeping the LT-HSC in an undifferentiated state in the BM 
niche (Wilson and Trumpp 2006). 
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In this work, the observed in vivo migratory pattern of the Lin--HSC when applied 
systemically in two animal models (discuss later) suggests that some chemokine 
receptors as well as integrins are very likely present in the cell surface once the 
suitable signal has been trigger in vivo. Assessing in vitro the response to migratory 
factors and time points of receptor expression would contribute to understanding the 
biological response of the population selected for this work. 
On the other hand, Lin--HSC resulted in silent expression of a number of 
inflammatory cytokine and growth factor transcript levels in contrast with the TBM 
population. There were reduced levels of all growth factors and cytokines analyzed by 
real time RT-PCR. This could be in part account for the unsuccessful per se EAE 
symptoms modulation of these Lin--HSC when applied in the relapsing stage of the 
disease. 
 
The potential utility of adult stem cells for gene therapy, tissue engineering, and 
treatment of neurological and other forms of disease is too significant to ignore. And 
yet knowledge and ability to deliver these forms of therapy in a safe and efficacious 
manner will require advances in the understanding of the basic biology of stem cells 
(Spangrude 2003). 
Two studies exemplifying the use of HSC for therapeutic purposes are the rescue of 
retinal degeneration (Otani, Dorrell et al. 2004) and the correction of metachromatic 
leukodystrophy (Biffi, De Palma et al. 2004). 
4.2. Induction of Experimental Autoimmune Encephalomyelitis  
An animal model sharing several neurodegenerative features with MS disease was 
induced following the described immunization protocol. The animals developed a 
progressive relapsing disease. Incidence of the disease and average clinical scores 
were acceptable and in agreement with previous reports (Eugster, Frei et al. 1999). 
Clinical symptoms were consistent with the change in body weight. Immuno-
histological analysis revealed a large number of cell-infiltrates in the spinal cord of the 
animals. Infiltrating cells were IsolectinB4 and CD45 positive and expected to be 
mainly in the demyelinated regions (Onuki, Ayers et al. 2001).  
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4.3. Migratory behavior and phenotype of Lin--HSC injected into 
EAE mice 
Under our experimental conditions, BM derived Lin--HSC infiltrated spinal cord and 
spleens after been injected into EAE mice at day 5 after first clinical manifestations. 
Although GFP+ Lin--HSC had not effect in the clinical course of EAE, cells showed 
specific migration towards demyelinating regions and therefore could be a useful tool 
for specific delivery of potential therapeutic factors into these lesion sites. 
 
Once in the spinal cord region, cells displayed a microglia/macrophage-like 
morphology in addition to the IsolectinB4 surface expression. At the same time, low 
levels of the pan-leukocyte marker CD45 was observed as reported before for CNS 
parenchymal microglia (Zhang, Li et al. 2002). Altogether these data seem to indicate 
that these cells derived from adult BM could present a microglial/macrophage-like 
phenotype in the EAE brain environment. A functional characterization (for instance a 
phagocytocis assay) would help to assess if these BM derived cells are indeed 
differentiated towards the above claimed phenotype once in the CNS. 
 
Data reporting migration of BM cells towards the CNS is broad, but controversy about 
the final fate they adopt once in the CNS still exists. As was the case for the 
morphology and surface marker found in the infiltrating cells during this work, several 
authors have reported the microglia/macrophage features displayed in cells that 
migrated into the CNS under BM transplantation or EAE conditions (Corti, Locatelli 
et al. 2002; Davoust, Vuaillat et al. 2006; Roybon, Ma et al. 2006). In contrast to these 
reports, Priller et al and Brazelton et al. claimed that these BM cells adopt a neuronal 
fate once in the brain (Brazelton, Rossi et al. 2000; Priller, Persons et al. 2001). 
Different experimental models and isolation protocols can be the reason for such 
dissimilarities.  
 
It is not inexpectable that the majority of cells coming from BM present a microglial 
phenotype in the CNS as a currently accepted idea is the renewal of microglia 
population by BM-derived precursor from the circulatory system. Nevertheless, in 
terms of local repair of damaged tissue it would be interesting to exactly assess which 
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conditions favour BM cells to adopt a particular phenotype (when certain cell type is 
desirable to be present in a therapy approach).  
In terms of therapeutic delivery of molecules, the migration and establishment of cells 
in the CNS is an attractive means to take advantage of. 
 
 4.4. Lentiviral gene transfer vectors for Lin--HSC 
In order to genetically manipulate the Lin--HSC looking towards a prospective clinical 
approach, a third generation lentiviral system was chosen for this work. In terms of 
bio-safety it is worthy to note that the elements present in the expression and 
packaging vectors of this gene transfer system are self-inactivating to prevent possible 
transcription of genes next to the integration site (Miyoshi, Blomer et al. 1998). 
Transduction levels of Lin--HSC assessed by reporter gene expression was around 
16% using a viral titer of 108 TU/ml.  
Application of lentiviral system to modify murine HSC is not widely reported, and 
publications are not consistent in HSC trasduction levels mentioned. Mikkola et al. 
showed up to 53 percent of GFP+ colonies (assessed by clonogenic progenitor assay 
from highly pure HSC). Reporter gene expression of the lentiviral vector used in this 
case was driven by the elongation factor-1 promoter and authors observed genetic 
mosaicism in the cell progeny. As is the case of the present work, cytokine stimulation 
was preferred during transduction and correlated with higher transduction efficiency 
levels (Mikkola, Woods et al. 2000). 
In contrast to the levels of transduction reported for lentiviral vectors in HSC from 
mice, transduction of human HSC (CD34+) has been widely described and high 
reporter gene expression was repeatedly shown (Akkina, Walton et al. 1996; Case, 
Price et al. 1999; Douglas, Kelly et al. 1999; Miyoshi, Smith et al. 1999; Kurre, 
Anandakumar et al. 2004). It is conceivable that an HIV-1 based vector system will be 
more efficient in human cells than in cells derived from other species, since humans 
are the natural host of the virus. 
 
Blockade of proteosome activity increased the levels of transduction up to 100 % in 
human HSC (Santoni de Sio, Cascio et al. 2006) as was not the case for this work 
where by a slight but not significant increase in the levels of transduction was 
observed after the same treatment.  
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In another report, the virus capside has been pseudotyped with early acting cytokines 
(TPO and SCF) and transduction of human HSC was enhanced (Verhoeyen, 
Wiznerowicz et al. 2005). In this report, fusion proteins between TPO or SCF and the 
N terminus of the MLV envelope glycoprotein were used to pseudotype the lentivirus 
particles. In addition functional display of the SCF and TPO on the viral particles was 
shown, which was not performed during the present work. 
A possible alternative to further obtain a highly transduced population would be the 
sorting of the cells of interest, but several disadvantages such as low yield, cell 
contamination and poor cell survival are common problems which are face when 
exploring this alternative. 
4.5. Lack of amelioration of EAE course by NT-3 over-expressing 
Lin--HSC 
After confirming a specific migratory pattern of the BM derived cells, a therapeutic 
approach was tested in this work. In order to give local support, a neurotrophic factor 
was chosen and over-expressed in the Lin--HSC cells before injecting to the animals at 
day 5 after first clinical manifestations. 
Contrary to the reduction of inflammation observed when applying the cells into the 
ischemic model (discuss later), the cells were not able per se to modify the course of 
the disease. It can be speculated that the time point in the EAE course of cell 
application correlates with an advanced stage of inflammation and myelin 
deterioration. An early cell application time could eventually lead to immune reaction 
amelioration as was observed in the ischemic model. Supporting a potential immune 
regulation when injecting bone marrow stem cells during EAE initiation, Zappia et al 
demonstrated amelioration of the disease through induction of T-cell anergy when 
bone marrow cells were injected at disease initiation (days 3 and 8 after 
immunization) (Zappia, Casazza et al. 2005). 
 
With regard to its neuroprotective effect as a therapeutic molecule, NT-3 has been 
previously shown to exert a positive effect in axonal injury (Guo, Zeng et al. 2006; 
Narazaki, de Barros Filho et al. 2006), so far data concerning its mode of action at the 
molecular level have not been published. 
In favor of the use of neurotrophic factors as a therapy approach for EAE, CNTF had 
shown a beneficial effect when administered daily in MOG33-55 induced mouse model. 
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Effects were mediated through a reduction of peri-vascular CNS infiltrates (Linker, 
Maurer et al. 2002; Kuhlmann, Remington et al. 2006). Similar effects in terms of 
reduction of inflammation were observed for NGF in a passive transfer EAE model in 
rats (Flugel, Matsumuro et al. 2001), and in the marmosets EAE model (Villoslada, 
Hauser et al. 2000).  
The therapeutic molecule administration scheme and the animal models used could be 
one possible difference to the work presented here. An effect for NT-3 when locally 
delivered has so far not been reported.  
Possible reasons for the unsuccessful treatment using NT-3 could be attributed to low 
availability due to improper local production/secretion of the factor by the Lin--HSC. 
Improvement of viral cell transduction titers and therefore gene expression would 
surely be desirable. Even a local application of NT-3 would eventually account for the 
efficacy and possible means of action of the molecule in EAE case. Additionaly to the 
NT-3 production, an in vitro functional assay of the neurotrophic molecule (e.g. 
induction of choline acetil transferase basal forebrain neurons primary culture, or 
promotion of embryonic dorsal root ganglia neuronal survival) would have shown 
proper factor activity. 
Although a currently concept of CNS therapy is by providing throphic support to 
damaged CNS environment, it is most likely that a combination of factors rather than 
a single one could be powerful enough for compensating the detrimental immune 
attack present in EAE. 
4.6. Application of Lin--HSC into a cerebral ischemia model and real 
time RT-PCR analysis of brains and spleens 
A therapeutic approach in an animal model of cerebral ischemia was tested by 
administration of Lin--HSC intravenously, 24 hours post-ischemia. Cells were found 
in the spleen before they selectively migrated to the lesioned hemisphere at 48-72 
hours after administration. In this regard, a time kinetics study may further illustrate 
the appearance of the cells in the CNS. Several reports have described the migration 
of BM cells to nervous tissue upon transplantation (Priller, Flugel et al. 2001; Simard 
and Rivest 2004). Even different time kinetics of cell entry was shown at 24 hours 
after ischemic insult. In this respect it must be considered that irradiation performed 
for the BM transplantation might have induced BBB alterations allowing the earliest 
time point entry of cells in these other report (Priller, Flugel et al. 2001).  
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Immunohistochemistry using surface markers for microglia/macrophage revealed the 
differentiation of the applied Lin--HSC to a microglia-like phenotype as was the case 
for cells found in the CNS in the EAE model. This part of the work supports the idea 
that the local environment of injured tissue plays certain role in determining the cell 
fate of transplanted HSC (Koshizuka, Okada et al. 2004). Hess et al. have reported 
that a microglial fate was adopted by BM transplanted cells, 3 month after going 
under MCAO (Hess, Abe et al. 2004). 
 
Despite the low number of Lin--HSC within the ischemic hemispheres at 72 hours 
post-ischemia, a decrease in the infarct volume and in the number of post-ischemic 
apoptotic cells was observed (Schwarting at al. submitted). Also in this case, as 
observed in EAE approach, the appearance of cells as resident microglia-like may 
potentially be used as a tool for gene therapy, in terms of delivery of therapeutic 
molecules directly to the site of injury.  
 
To check if Lin--HSC could mediate a neuroprotective effect in the ischemic 
micromilieu real time RT-PCR for gene transcription levels of several neurotrophic 
factors and cytokines was performed in brain hemispheres. Surprisingly, no significant 
changes in the neurotrophic factors between HSC and PBS-injected animals were 
found. A slight but non-significant reduction in the proinflammatory cytokines TNF-α 
and IFN-γ gene expression levels was detected. In parallel, a decreased in microglia 
activation in the ischemic hemisphere was observed.  
Since the absolute number of Lin--HSC detected within the ischemic hemisphere at 72 
hours after injection is relatively low to mediate a local environment change, one 
could speculate the systemically applied cells are able to reduce the peripheral 
immune activation in an earlier time point during cerebral ischemia, which in turn 
leads to reduced migration of peripheral immune cells into the ischemic lesion.  
To that regard, real time RT-PCR assessing cytokine and chemokine receptors 
expression status was checked in spleens of the injured animals and compared to 
healthy ones. 
 
It must be mentioned that Lin--HSC were detected in secondary immune organs such 
as the spleen at 24 hours after application. Although RT-PCR values presented are 
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non-significant (due to a low number of samples) it clearly shows a tendency of the 
Lin--HSC treatment to counter-regulate the ischemia induced up-regulation of 
inflammatory cytokines in the spleens and the chemokine receptor expression, which 
is in accordance with the reduced recruitment of immune cells to the ischemic lesion. 
A recent study reported the systemically activated immune system within 22 hours 
after MCAO (Offner, Subramanian et al. 2006).  
More spleen samples are needed to complement this observations and additional 
studies showing interactions between Lin--HSC and splenocytes would contribute to a 
better understanding of the observed effects.  
 
 
Although no clinical effects were observed when applying Lin--HSC to the animal 
model of MS, in this second part of the work a novel neuroprotective effect by Lin--
HSC in an experimental model of cerebral ischemia is shown. Future investigations 
are open for testing further gene and cell therapies in the context of neurodegenerative 
diseases and prospective clinical applications should eventually be considered after 
detailed understanding of the molecular and cellular therapeutic basis. 
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5. Summary 
Multiple Sclerosis (MS) and cerebral ischemia are severe neurodegenerative diseases. 
Treatment in both cases is inadequate as drug delivery to the central nervous system 
(CNS) represents a difficulty due to the presence of the blood-brain-barrier (BBB) and 
its control of molecule trafficking. The migration and integration into CNS 
parenchyma of adult stem cells coming from bone marrow (BM) has been widely 
reported, suggesting their potential as a cellular therapy in themselves, but also as 
means of local delivery of therapeutic agents.  
In this work, the isolation of a cell population derived from the mouse BM, which is 
enriched in hematopoietic progenitor/stem cells (here termed Lin--HSC) and their 
application in two neurodegenerative paradigms: the animal model for MS, EAE, and 
the animal model for cerebral ischemia were described. Furthermore, the use of these 
cells as a delivery system for a potential therapeutic factor, Neurotrophin-3 was 
studied. 
Lin-- HSC were isolated and characterized by flow cytometry and quantitative real 
time RT-PCR. Lin--HSC showed no expression of blood lineage differentiated cells 
neither of chemokine receptors and integrins, but were positive for c-kit (29%) and 
CD45 (58%).  
Relative gene transcript levels of BDNF, bFGF, GDNF, NGF, NT3, TGF-ß, VEGF 
were not relevant in the Lin--HSC population when compared to total BM. While the 
inflammatory cytokines TNF-α, IFN-γ and IL-1ß where reduced in comparison with 
total BM that contains already matured blood cells. 
The EAE model was induced by active immunization with myelin oligodendrocyte 
glycoprotein. GFP positive Lin--HSC were intravenously injected at day 5 after first 
clinical symptoms. Five days after application, cells were found to migrate and remain 
specifically in the lesion sites of the spinal cord. On average 25.4±14.5 cell/mm2 were 
found, they down-regulated their CD45 expression while being positive for the 
IsolectinB4 marker. Therefore a microglial/macrophage-like phenotype of the 
migrated cells is suggested. Lin--HSC were not able to interfere with the EAE 
symptoms when injected alone, or genetically modified to over-express a 
neuroprotective factor, Neurotrophin-3. At an advanced state of inflammation, poor 
local release of the NT-3 factor could explain the luck of success of this approach. 
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The animal model of cerebral ischemia was established by middle cerebral aorta 
occlusion. Lin--HSC were injected 24 hours after ischemia induction. Lin--HSC 
migrated in this model into the peri-infarct zone after intravenous application. Cells 
found in the brain displayed an IsolectinB4 and CD11b marker positive phenotype. 
Brain hemispheres of Lin--HSC injected mice showed a reduced infarct size and a 
decreased recruitment of inflammatory cells to lesion sites when compared with PBS 
injected controls. Analysis by real time RT-PCR showed that Lin--HSC were not able 
to give direct trophic support within ischemic regions but rather influenced by 
reducing peripheral immune activation as expression levels of a number of cytokines 
and chemokine receptors were seen to be down-regulated in the spleens derived from 
cell treated animals.  
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